US20140212490A1 - Tablet for pulsed delivery - Google Patents
Tablet for pulsed delivery Download PDFInfo
- Publication number
- US20140212490A1 US20140212490A1 US14/228,817 US201414228817A US2014212490A1 US 20140212490 A1 US20140212490 A1 US 20140212490A1 US 201414228817 A US201414228817 A US 201414228817A US 2014212490 A1 US2014212490 A1 US 2014212490A1
- Authority
- US
- United States
- Prior art keywords
- enteric
- active ingredient
- tablet
- host
- pharmaceutical tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Definitions
- This invention relates to a pharmaceutical composition in tablet form that provides for both immediate and enteric release of an active drug agent, and also relates to the use and formulation of such pharmaceutical composition. More particularly, the present invention relates to a drug delivery system, in tablet form, that is comprised of an immediate release portion and a delayed release portion.
- an immediate release portion of the pharmaceutical composition contains an active ingredient, from which portion the initiation of release of said active agent is not substantially delayed after ingestion of the pharmaceutical composition.
- a delayed release portion of the pharmaceutical composition contains an active ingredient, from which portion the initiation of release of said active agent is substantially delayed after ingestion of the pharmaceutical composition.
- the delayed release portion comprises an enteric coated layer, within which enteric coated layer there is a core tablet containing at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric coated minitablet dosage forms containing an active ingredient.
- a delayed release portion that comprises a core tablet that includes an enteric coating, such that the core tablet does not disintegrate in the stomach; i.e., the core tablet disintegrates in the intestine.
- an immediate release portion whereby the enteric coated core tablet has a non-enteric coating over all or a portion of the enteric coating and this non-enteric coating provides for an immediate release of active that is contained therein; i.e., the immediate release portion releases active ingredient in the stomach.
- the core tablet includes therein particles and/or mini-tablets (“mini-tabs”) that include therein an active agent and that have an enteric coating to thereby delay release of active agent from the particles and/or mini-tablets until a time that is subsequent to the disintegration of the core tablet in the intestine. Additionally, the core tablet may or may not include a dosage of uncoated active ingredient the release of which is initiated at the time that the core tablet disintegrates in the intestine.
- the core tablet is itself enteric-coated thereby to ensure its disintegration in the post-stomach GI tract.
- the matrix of the core tablet includes enteric materials that maintain the structure of the core tablet to thereby ensure its disintegration in the post-stomach GI tract, whereby coating the core tablet with an enteric coating is not necessary, though is still preferred.
- the core tablet may be either, a multiparticulate core: containing one or more pellet types, designed to release drug in the post-stomach portions of the GI tract, wherein the pellet types provide about 1 to 95% of total core tablet weight; or a mini-tab core: containing one or more mini-tabs also designed to release drug in the post-stomach GI tract, wherein the mm-tabs provide about 1 to 95% of total core tablet weight.
- the enteric polymer layer can be produced by spraying a number of different types of enteric polymers on top of the above-described core tablet. Thus, the enteric polymer coating delays the disintegration of the core tablet until the core tablet reaches the intestine. Additionally, the multiparticulates or mini-tabs comprising the core tablet may be formulated with further delayed and/or modified release materials, to thereby further delay and/or modify release of the active drug agents released therefrom.
- the immediate release portion may be an immediate release drug layer that can be sprayed on top of the enteric-coated core tablet to thereby serve as an immediate releasing portion of the drug delivery system.
- the immediate release drug layer completely engulfs the enteric polymer coated core tablet.
- the immediate release drug layer does not completely engulf the enteric polymer coating of the core tablet; in this embodiment a portion of the enteric polymer coating is exposed.
- the immediate release portion may comprise one layer of a bi-layer tablet in conjunction with the enteric-coated core tablet, or the immediate release portion may comprise a plurality of layers in a multi-layer tablet in conjunction with the enteric-coated core tablet.
- the instant invention is also directed to a process for treating a patient in need of treatment with an active medicinal agent, which comprises administering to the patient the hereinabove and hereinbelow described pharmaceutical compositions containing such an active medicinal agent.
- the instant invention is also directed to a method of making the hereinabove and hereinbelow described pharmaceutical compositions.
- enteric coating includes both coatings that are pH-sensitive and coatings that are pH-independent. More particularly the term “enteric coating” as used herein indicates that the coating is one that is selected for its ability to deliver active ingredients to the post-stomach GI tract.
- enteric coated tablet means a tablet that is capable of delivering one or more pulses of active drug agent into the small intestinal region of the GI tract.
- enteric coated tablet is not limited to tablets engulfed by, or overlayed with, an enteric coating, but includes tablets having matrices comprising enteric materials that maintain the unit integrity of the core tablet at least until such tablet is delivered to the intestine.
- the core tablet of the instant invention is an enteric coated tablet in that it permits the delivery of a multi-particulate comprised (mini-tab, bead, microparticle, etc.) tablet into the GI tract as an intact unit. It is a beneficial aspect of the invention that the core tablet is passed from the stomach to the intestine substantially intact and that the core tablet does not disintegrate in the stomach.
- mini-tabs are formulated so that they are small enough to fit into a standard sized tablet core.
- the mini-tabs can be coated with an enteric coating that is either a delayed release and/or modified release coating.
- the mini-tabs are coated with a delayed release coating.
- there is a plurality of different mini-tabs in that each is coated with a delayed release coating that results in each different mini-tab initiating release of active ingredient therefrom at different times, each of which different times is subsequent to the time at which the core tablet enters the small intestine.
- a core tablet may comprise one or more mini-tabs each consisting of the same drug agent or different drug agents, along with known pharmaceutical fillers.
- the core tablet is thereafter coated with an enteric coating that is either a delayed release or a modified release coating.
- the immediate release portion containing an active drug agent may thereafter be layered over at least a portion of the enteric-coated core tablet to provide an immediate release of a desired active drug agent.
- additional enteric materials are used to formulate the matrix of the above-described tablet core to thereby further modify release of active ingredient therefrom.
- an enteric polymer is sprayed on top of the core tablet, wherein enteric materials are used in formulating the matrix of the tablet core.
- additional enteric materials are used to formulate the beads or mini-tabs of the above-described tablet core to thereby further modify release of active ingredient therefrom.
- an enteric polymer is sprayed on top of the core tablet, wherein enteric materials are used in formulating the beads or mini-tabs of the tablet core.
- the core tablet comprises at least one mini-tab and an uncoated dosage of active ingredient, whereby after the core tablet's disintegration in the small intestine the uncoated dosage of active ingredient is immediately released at a first time and thereafter the at least one mini-tab initiates release of the active ingredient contained therein at a second time that is subsequent to said first time.
- This embodiment delivers at least three separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the uncoated dosage of active ingredient and the at least one mini-tab deliver later-initiated pulses in the intestine, whereby the initiation of release of active ingredient from the at least one mini-tab is subsequent to the initiation of release of active ingredient from the uncoated dosage of active ingredient.
- the core tablet comprises at least two different mini-tabs, whereby after the core tablet's disintegration in the small intestine the first of the at least two different mini-tabs initiates release of the active ingredient contained therein at a first time, and the second of the at least two different mini-tabs initiates release of the active ingredient contained therein at a second time that is subsequent to said first time.
- This embodiment delivers at least three separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the at least two different mini-tabs deliver later-initiated pulses in the intestine, whereby the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab.
- the core tablet comprises at least two mini-tabs and an uncoated dosage of active ingredient, whereby after the core tablet's disintegration in the small intestine the uncoated dosage of active ingredient is immediately released at a first time and thereafter the at least two mini-tabs initiate release of the active ingredients contained therein at second and third times that are each subsequent to said first time.
- This embodiment delivers at least four separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the uncoated dosage of active ingredient and the at least two mini-tabs deliver later-initiated pulses in the intestine, whereby, the initiation of release of active ingredient from the at least two mini-tabs is subsequent to the initiation of release of active ingredient from the uncoated dosage of active ingredient, and the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab.
- the core tablet comprises at least three different mini-tabs, whereby after the core tablet's disintegration in the small intestine the first of the at least three different mini-tabs initiates release of the active ingredient contained therein at a first time, the second of the at least three different mini-tabs initiates release of the active ingredient contained therein at a second time that is subsequent to said first time, and the third of the at least three different mini-tabs initiates release of the active ingredient contained therein at a third time that is subsequent to said second time.
- This embodiment delivers at least four separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the at least three different mini-tabs deliver later-initiated pulses in the intestine, whereby the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab, and the initiation of release of active ingredient from the third mini-tab is subsequent to the initiation of release of active ingredient from the second mini-tab.
- the core tablet comprises at least three mini-tabs and an uncoated dosage of active ingredient, whereby after the core tablet's disintegration in the small intestine the uncoated dosage of active ingredient is immediately released at a first time and thereafter the at least three mini-tabs initiate release of the active ingredients contained therein at second, third, and fourth times that are each subsequent to said first time.
- This embodiment delivers at least five separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the uncoated dosage of active ingredient and the at least three mini-tabs deliver later-initiated pulses in the intestine whereby, the initiation of release of active ingredient from first of the at least three mini-tab is subsequent to the initiation of release of active ingredient from the uncoated dosage of active ingredient, the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab, and the initiation of release of active ingredient from the third mini-tab is subsequent to the initiation of release of active ingredient from the second mini-tab.
- the present invention may be used to decrease the variability of the absorption of any active drug agent, and it is particularly useful for decreasing the absorption variability of antibiotics.
- the invention is more particularly useful for decreasing the absorption variability of beta-lactam antibiotics, cephalosporin antibiotics, and macrolide antibiotics. Even more particularly, it is useful for decreasing the absorption variabilities of amoxicillin and clarithromycin, both in separate formulations, and in formulations that combine amoxicillin and clarithromycin.
- This dumping of pellets into the stomach can lead to pellet spread and a decrease in the strength of the pulses, resulting in significant variations in in vivo pharmacokinetics. Those variations can be expressed in any or all of Cmax, Tmax, Lag Time, and AUC.
- the dumping can also lead to local site concentration dilution.
- the present invention avoids these problems through a pulsatile dosing profile, whereby the drug is released in the GI tract in a staged manner, creating an increase and decrease in plasma levels over time.
- these components can be engineered to release drag in a staged, or sequential burst, fashion to achieve pulsatile plasma levels such as are described in U.S. Pat. Nos. 6,544,555 and 6,723,341, the disclosures of which are hereby incorporated in their entireties.
- the enteric-coated core tablet of the present invention is large enough that it does not pass through the pyloric sphincter until after the pyloric sphincter opens to discharge stomach contents into the small intestine.
- the size of the microparticulates or mini-tabs incorporated into the core tablet does not effect the performance of the product since they are enveloped in the core tablet/enteric coating system, that is emptied as a unit into the small intestine. Accordingly, the size of microparticles and mini-tabs that comprise the core tablet can be relatively small in comparison to the core tablet.
- the present invention overcomes the earlier-discussed dumping problems. This allows the pellets or mini-tabs to enter the small intestine as a single bulk unit, thereby avoiding the gradual gastric emptying effects that plague the current art. By creating an outer drug layer an immediate release pulse is also provided.
- the benefits of the present invention are not limited to a reduction of in vivo pharmacokinetic variabilities.
- the instant dual phase delivery paradigm is capable of facilitating high dose loading of a desired drug, and may deliver multiple pulses thereof. Additionally, the instant invention can deliver multiple drugs within the same dosing unit. This multi-dosing aspect allows the instant invention to deliver incompatible drug substances from the same tablet core. It also ensures that the delivery of one drug substance, or pulse of a drug substance, is not delivered until the desired previous substance, or pulse of a drug substance is delivered.
- the tablet of the present invention can also be used to deliver drugs that may be incompatible in the same dosage form, but which, when presented to the small intestine in combination via the core tablet, will work in tandem with respect to improving absorption or combating specific infectious problems.
- the instant invention also allows different regions of the GI tract to be specifically targeted for delivery. Also, the invention allows for once-a-day dosing to better ensure patient compliance; this avoids the possibility of overdosing the patient as only a portion of the drug is delivered at any time during the day. Furthermore, the instant invention permits for a smaller tablet size than can be achieved by way of more traditional multi-particulate tablets.
- the pellets present greater surface area owing to the different functional coatings and different amounts of functional coatings that are applied to the pellets to create the pulsatile release in the GI tract.
- the traditional microparticulate tablet size is increased further still by the additions of the various fillers that hold the coated pellets together.
- much of the volume is occupied by the high polymer content of the individual pellets.
- the first pulse is a coated layer on the surface of the enteric-coated core tablet, and the second pulse may be provided by the granulation inside the enteric coated core tablet that may also function as a cushioning agent or binder to hold the third pulse pellets together.
- the present invention provides a tablet in which the earlier pulses are concentrated and more dense, thereby presenting less surface area, and hence occupying less volume, in the tablet.
- the instant drug delivery system allows the formulator to engineer pulses that release at any desired time.
- the core tablet of the present invention contains an active drug agent in the form of a prepared compactable matrix and/or compacted pellet, bead, or mini-tab.
- the pharmaceutical active agent is contained within the enteric-coated core tablet for modified delivery, and a drug layer on top of the enteric-coated tablet provides immediate release delivery.
- a drug layer on top of the enteric-coated tablet provides immediate release delivery.
- the core tablet may comprise of either or both of a multiparticulate active (pellet or bead) and/or a compressible active granule and/or matrix and/or mini-tab.
- a matrix could be made up of an active ingredient with enhancers to improve bioavailability or solubility of the active ingredient depending on limitations inherent to the particular active ingredient absorption characteristics. Active ingredient absorption limitations might be influenced by any or all of moisture content, pH, or active transport mechanisms.
- a typical pellet or multiparticulate active must be “robust” in that it must be capable of withstanding downstream processing activities. These processing operations may include, but are not limited to: wet granulation, extrusion, spheronization, fluid bed drying, fluid bed coating, roller compaction, tablet compression forces, and pan coating.
- Non-limiting examples of such myriad other active drug agents include other anti-infective agents such as the antifungals and the antivirals, and antineoplastic agents.
- antibiotics have been used, and will be used, in order to combat bacterial infection.
- such antibiotics can be administered by a repeated dosing of immediate release dosage forms, which results in poor compliance, or as controlled release formulations (slow release) at higher administered doses.
- the present invention is directed to providing for an improved antibiotic product.
- an antibiotic pharmaceutical product as described hereinabove and hereinbelow, which contains at least two, preferably at least three, antibiotic dosage forms.
- Such dosage forms are formulated so that each of the dosage forms has a different release profile.
- a single or unitary antibiotic product that has contained therein at least two, preferably at least three antibiotic dosage forms, each of which has a different release profile, whereby the antibiotic contained in each of such dosage forms is released at different times.
- the antibiotic product may be comprised of at least four different dosage forms, each of which starts to release the antibiotic contained therein at different times after administration of the antibiotic product.
- the antibiotic product generally does not include more than five dosage forms different release times.
- the antibiotic product has an overall release profile such that when administered the maximum serum concentration of the total antibiotic released from the product is reached in less than twelve hours, preferably in less than eleven hours. In an embodiment, the maximum serum concentration of the total antibiotic released from the antibiotic product is achieved no earlier than four hours after administration.
- one of the at least two dosage forms is an immediate release dosage form whereby initiation of release of the antibiotic therefrom is not substantially delayed after administration of the antibiotic product.
- the second of the at least two dosage forms is an enteric dosage form, whereby the antibiotic released therefrom is delayed until after initiation of release of the antibiotic from the immediate release dosage form, and is further delayed until after the second dosage form (contained in the core tablet) has passed through the pyloric sphincter of the stomach and into the intestinal portion of the GI tract. More particularly, the antibiotic released from the second of the at least two dosage forms achieves a C max (maximum serum concentration in the serum) at a time after the antibiotic released from the first of the at least two dosage forms achieves a C max in the serum.
- C max maximum serum concentration in the serum
- one of the at least three dosage forms is an immediate release dosage form whereby initiation of release of the antibiotic therefrom is not substantially delayed after administration of the antibiotic product.
- the second and third of the at least three dosage forms are enteric dosage forms, whereby the antibiotic released therefrom is delayed until after initiation of release of the antibiotic from the immediate release dosage form and is further delayed until after the second and third dosage forms (contained in the core tablet) have passed through the pyloric sphincter of the stomach and into the intestinal portion of the GI tract.
- the antibiotic released from the second of the at least three dosage forms achieves a C max (maximum serum concentration in the serum) at a time after the antibiotic released from the first of the at least three dosage forms achieves a C max in the serum, and the antibiotic released from the third dosage form achieves a C max in the serum after the C max of antibiotic released from the second dosage form.
- the antibiotic is a beta-lactam antibiotic, a cephalosporin antibiotic, or a macrolide antibiotic.
- the antibiotic is amoxicillin.
- the antibiotic is clarithromycin.
- the tablet contains both amoxicillin and clarithromycin.
- the antibiotic is amoxicillin and the compliment of amoxicillin released from each subsequently releasing dosage form expresses a maximum concentration in the serum that is equal to or exceeds the maximum concentration in the serum that is expressed by the compliment of amoxicillin released by the dosage form immediately preceeding that subsequently-releasing dosage form.
- the second of the at least three dosage forms initiates release of the antibiotic contained therein at least one hour after the first dosage form, with the initiation of the release therefrom generally occurring no more than six hours after initiation of release of antibiotic from the first dosage form of the at least three dosage forms.
- the immediate release dosage form produces a C max for the antibiotic released therefrom within from about 0.5 to about 2 hours
- the second dosage form of the at least three dosage forms producing a C max for the antibiotic released therefrom within about 6 hours.
- the C max for such second dosage form is achieved no earlier than two hours after administration of the antibiotic product; however, it is possible within the scope of the invention to achieve C max in a shorter period of time.
- the antibiotic product may contain at least three or at least four or more different dosage forms.
- the antibiotic released therefrom reaches a C max at a time later than the C max is achieved for the antibiotic released from each of the first and second dosage forms.
- release of antibiotic from the third dosage form is started after initiation of release of antibiotic from both the first dosage form and the second dosage form.
- C max for antibiotic release from the third dosage form is achieved within eight hours.
- the antibiotic product contains at least four dosage forms, with each of the at least four dosage forms having different release profiles, whereby the antibiotic released from each of the at least four different dosage forms achieves a C max at a different time.
- C max for all the antibiotic released from the antibiotic product is achieved in less than twelve hours, and more generally is achieved in less than eleven hours.
- the antibiotic product is a once a day product, whereby after administration of the antibiotic product, no further product is administered during the day; i.e., the preferred regimen is that the product is administered only once over a twenty-four hour period.
- the preferred regimen is that the product is administered only once over a twenty-four hour period.
- a single dosage antibiotic product comprised of at least three antibiotic dosage forms each having a different release profile is an improvement over a single dosage antibiotic product comprised of an antibiotic dosage form having a single release profile.
- Each of the dosage forms of antibiotic in a pharmaceutically acceptable carrier may have one or more antibiotics and each of the dosage forms may have the same antibiotic or different antibiotics.
- the dual phase delivery system herein described is not restricted thereto, and may also be used for twice-a-day administration of drugs that have more limited windows of absorption.
- the fourth of the at least four dosage form may be a sustained release dosage form or a delayed release dosage form. If the fourth dosage form is a sustained release dosage form, even though C max of the fourth dosage form of the at least four dosage forms is reached after the C max of each of the other dosage forms is reached, antibiotic release from such fourth dosage form may be initiated prior to or after release from the second or third dosage form.
- the antibiotic product of the present invention is formulated in a manner such that it is suitable for oral administration.
- the immediate release drug layer of the product sprayed onto the enteric coated core tablet generally provides from about 5% to about 85% of the total dosage of antibiotic to be delivered by the product, with such immediate release drug layer generally providing at least 30-40% of the total dosage of the antibiotic to be delivered by the product.
- the immediate release drug layer provides from about 30% to about 40% of the total dosage of antibiotic to be delivered by the product; however, in some cases it may be desirable to have the immediate release drug layer provide for about 5% to about 20% or 75% to about 85% of the total dosage of antibiotic to be delivered by the product.
- each of the delayed release dosage forms may provide about equal amounts of antibiotic; however, they may also be formulated so as to provide different amounts.
- each of the dosage forms may contain the same antibiotic. In accordance with one embodiment of the present invention, each of the dosage forms may contain different antibiotics. In accordance with one embodiment of the present invention each of the dosage forms may contain more than one antibiotic.
- the immediate release component provides from 5% to 85% (preferably 30% to 40%), by weight, of the total antibiotic; where there are three delayed release components, the immediate release component provides from 5% to 75%, by weight, of the total antibiotic; and where there are four delayed release components, the immediate release component provides from 5% to 70%, by weight, of the total antibiotic.
- the first delayed release component (the one released earlier in time) provides from 5% to 75%, by weight, of the total antibiotic provided by the two delayed release components with the second delayed release component providing the remainder of the antibiotic.
- the earliest released component provides 5% to 75% by weight of the total antibiotic provided by the three delayed release components
- the next in time delayed release component provides from 5% to 75%, by weight, of the antibiotic provided by the three delayed release components and the last in time providing the remainder of the antibiotic provided by the three delayed release components.
- the earliest delayed release component provides from 5% to 75%, by weight
- the next in time delayed release component provides from 5% to 75%, by weight
- the next in time delayed release component provides from 5% to 75%, by weight
- the last in time delayed release component provides from 5% to 75%, by weight, in each case of the total antibiotic provided by the four delayed release components.
- the materials to be added to the active ingredients for the immediate release component can be, but are not limited to, microcrystalline cellulose, corn starch, pregelatinized starch, potato starch, rice starch, sodium carboxymethyl starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose, chitosan, hydroxychitosan, hydroxymethylatedchitosan, cross-linked chitosan, cross-linked hydroxymethyl chitosan, maltodextrin, mannitol, sorbitol, dextrose, maltose, fructose, glucose, levulose, sucrose, polyvinylpyrrolidone (PVP), acrylic acid derivatives (Carbopol, Eudragit, etc.), polyethylene glycols, such a low molecular weight PEGs (PEG2000-10000) and high molecular weight PEGs (Polyox) with molecular weights above 20,000 daltons.
- ingredients in this system may be useful to have other ingredients in this system to aid in the dissolution of the drug, or the breakdown of the component after ingestion or administration.
- These ingredients can be surfactants, such as sodium lauryl sulfate, sodium monoglycerate, sorbitan monooleate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, glyceryl monostearate, glyceryl monooleate, glyceryl monobutyrate, one of the non-ionic surfactants such as the Pluronic line of surfactants, or any other material with surface active properties, or any combination of the above.
- surfactants such as sodium lauryl sulfate, sodium monoglycerate, sorbitan monooleate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, glyceryl monostearate, glyceryl monooleate, glyceryl monobutyrate, one of the non-ionic
- compositions in this composition are the same immediate release unit, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- Materials that can be used to obtain a delay in release suitable for this component of the invention can be, but are not limited to, polyethylene glycol (PEG) with molecular weight above 4,000 daltons (Carbowax, Polyox), waxes such as white wax or bees wax, paraffin, acrylic acid derivatives (Eudragit), propylene glycol, and ethylcellulose.
- PEG polyethylene glycol
- Carbowax, Polyox polyethylene glycol
- waxes such as white wax or bees wax
- paraffin acrylic acid derivatives
- acrylic acid derivatives Eudragit
- propylene glycol and ethylcellulose
- compositions in this composition are the same as the immediate release component, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- the kind of materials useful for this purpose can be, but are not limited to, cellulose acetate phthalate, Eudragit L, and other phthalate salts of cellulose derivatives.
- compositions in this composition are the same as the Immediate release component, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- the kind of materials useful for this purpose can be, but are not limited to, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylcellulose, nitrocellulose, Eudragit R, and Eudragit RL, Carbopol, or polyethylene glycols with molecular weights in excess of 8,000 daltons.
- antibiotics that may be used in the product of the invention: Cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephacelor, cephprozil, cephachine, cefamandole, cefonicid, ceforanide, cefuroxime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, cefinetazole, cefotetan, cefoxitin, loracarbef, imipenem, erythromycin (and erythromycin salts such as estolate, ethylsuccinate, gluceptate, lactobionate, stearate), azithromycin, clarithromycin, dirithromycin, troleandomycin, penicillin V, penicillin salts, and complexes, methicillin, cefadroxil, ce
- antivirals that may be used in the product of the invention: Acyclovir, Amantadine, Amprenavir, Cidofovir, Delavirdine, Didanosine, Famciclovir, Foscarnet, Ganciclovir, Indinavir, Interferon, Lamivudine, Nelfinavir, Nevirapine, Palivizumab, Penciclovir, Ribavirin, Rimantadine, Ritonavir, Saquinavir, Stavudine, Trifluridine, Valacyclovir, Vidarabine, Zalcitabine, Zidovudine.
- amphotericin B flucytosine, fluconazole, griseofulvin, miconazole nitrate, terbinafine hydrochloride, ketoconazole, itraconazole, undecylenic acid and chloroxylenol, ciclopirox, clotrimazole, butenafine hydrochloride, nystatin, naftifine hydrochloride, oxiconazole nitrate, selenium sulfide, econazole nitrate, terconazole, butoconazole nitrate, carbol-fuchsin, clioquinol, methylrosaniline chloride, sodium thiosulfate, sulconazole nitrate, terbinafine hydrochloride, tioconazole, tolnaftate, undecylenic acid and undecylenate salts (calc
- Dissolve binder and liquid ingredients in water Place solid ingredients into a high shear blender (e.g. Glatt) and mix at low impeller speed (300 rpm) for 1 minute. At an impeller speed of 300 rpm and a chopper speed of 2500 rpm, slowly add the prepared binder solution to the dry mix (3-5 minutes). Add additional water as necessary. Continue to mix for 30 sec. Discharge material and transfer to an extruder. Extrude the granulation with a dome extruder at 50-100 rpm through a 0.6-1 mm, or other appropriate, screen. Transfer the extrudate into a spheronizer. Spheronize at 610 rpm for 20-30 sec.
- a high shear blender e.g. Glatt
- Discharge pellets and transfer to a fluidbed dryer (FluidAir). Dry at 60° C. inlet temp and 200 air flow until the loss on drying (LOD) does not change any further (approx. 60 min). Cool down the pellets at 25° C. air temperature for approximately 15 minutes prior to discharge.
- FluidAir Fluidbed dryer
- Preparation of the coating solution Dissolve sodium lauryl sulfate (SLS) and triethyl citrate (TEC) in water using an overhead mixer. Add polymer and mix for 30-45 ruin. Add Talc and mix for 30-45 min. Sieve dispersion across a 60 mesh screen prior to use. Continue mixing during the entire coating process in the fluidbed. Transfer the pellets to a pre-heated fluidbed dryer (FluidAir). Apply the coating solution to the pellets spraying at 60-65° C. inlet temp, 170-180 scfm air flow and 30 psi atomization air pressure up to 40% weight gain. Dry pellets at 50° C. and 10 psi for 10 minutes, and cool at 30° C. prior to discharge. Sieve the final product across 20-40 mesh. Yield is typically>95%.
- Dissolve binder in water Place the active pharmaceutical ingredient into a high shear blender (e.g. Glatt). At impeller speed 300 rpm and chopper speed 2500 rpm, slowly add the binder solution (3-5 minutes). Add additional water if necessary. Continue to mix for 30 sec. Discharge material and transfer to a fluidbed dryer. Dry the granulation at 50° C. for 60 minutes. Mill through a Comil U10 at speed 50 using screen 7A040603122329B(1016)90. Dry in fluidbed for 30 minutes at 50° C. Sieve across a 20 mesh screen.
- a high shear blender e.g. Glatt
- enteric coating solution mix L30D and TEC for 30 minutes at low speed using an overhead mixer.
- mix water and talc stirring vigorously.
- Sieve through 60 mesh screen prior to coating process.
- Coat tablets in a pan coater (LCDS) at 55° C. inlet temperature, 25 cfm air flow, pump setting of 7-10, pan speed 19 rpm, and atomization pressure of 25-26 psi. Up to 8% weight gain is required for this coating procedure. Yields are typically>95%.
- a solution of 7% opadry solution in water is prepared by stirring.
- the coating is applied at inlet temp of 65° C., airflow 25 cfm, pump setting 8-9, pan speed 19 rpm, and 25 psi atomization air pressure to reach a total weight gain of 3-3.5%.
- Active Pharmaceutical Ingredient 85-95% Microcrystalline Cellulose 4-8% Povidone 1-5% PEG-35 Castor Oil 0.5-2% Water As needed
- Active Pharmaceutical Ingredient 1-15% Microcrystalline Cellulose 69-91% Povidone 3-6% PEG-35 Castor Oil 5-10% Water As needed These immediate release pellets can also be coated with an enteric or modified release coating to deliver active ingredient to the required locations in the GI tract.
- Active Granule 30-40% Enteric Coated Pellets 1-15% Microcrystalline Cellulose 40-60% Povidone K30 1-5% Croscarmelose Sodium 1-5% Magnesium Stearate 1-3%
- enteric polymers include, but are not limited to polyethyl acrylate, methyl methacrylate, ethyl acrylate, and trimethylammonioethyl methacrylate chloride copolymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, ethylvinylacetate phthalate, polyvinylacetate phthalate, and carboxymethylethylcellulose.
- Tablet contents i.e.
- the active matrix/pellets are encapsulated and protected from releasing before the targeted release point.
- the coating must withstand downstream processing from farther tablet compression forces and/or tablet coating operations.
- the enteric coating should protect the active contents as they pass through the upper GI tract and stomach until reaching the desired trigger point within the small or large intestine. This will ensure that all of the tablet contents will be emptied as a single packet at the target and prevent separation and dilution of the drug during transit.
- Methacrylic Copolymer 20-60% Talc 1-30% Triethyl Citrate 1-20% Sodium Lauryl Sulfate 0.25-1.0% Water As needed
- the active pharmaceutical layer or drug layer is applied on top of the protected enteric coated core tablet.
- the active layer delivers the first pulse or immediate release.
- composition of the Amoxicillin trihydrate matrix pellets provided in Table 1.
- composition of the aqueous Eudragit L30D-55 dispersion applied to the amoxicillin matrix pellets is provided below in Table 2.
- composition of the aqueous Eudragit® S 100 dispersion applied to the Amoxicillin matrix pellets is provided below in Table 3.
- Eudragit ® S 100 Aqueous Coating Dispersion Component Percentage (%) Part A Eudragit ® S 100 10.0 1N Ammonium Hydroxide 5.1 Triethyl Citrate 5.0 Water 64.9 Part B Talc 5.0 Water 10.0 Solid Content 25.0 Polymer Content 10.0
- the following coating parameters were used for both the Eudragit® L 30 D-55 and Eudragit® S 100 aqueous coating processes.
- enteric coating solution mix L30D and TEC for 30 minutes at low speed using an overhead mixer, according to Table 2.
- mix water and talc stirring vigorously.
- Sieve through 60 mesh screen prior to coating process. Keep stirring the dispersion at slow speed throughout the coating process.
- Coat tablets in a pan coater at 55° C. inlet temperature, 25 cfm air flow, pump setting of 7-10, pan speed 19 rpm, and atomization pressure of 25-26 psi. Up to 8% weight gain is desired for this coating procedure.
- a solution of 7% opadry solution in water is prepared by stirring.
- the coating is applied at inlet temp of 65° C., airflow 25 cfm, pump setting 8-9, pan speed 19 rpm, and 25 psi atomization air pressure to reach a total weight gain of 3-3.5%.
- This example makes a complete amoxicillin enteric coated tablet with 4 pulses containing 500-800 mg amoxicillin.
- Clarithromycin Pellets Component Percentage (%) Clarithromycin 50.6 Lactose monohydrate, spray dried 32.1 Silicified microcrystalline cellulose 14.6 Polyoxyl 35 Castor Oil* 1.7 Hydroxypropyl methylcellulose* 1.0 Total 100 *Hydroxypropyl methylcellulose and Polyoxyl 35 were added as an 8.7% w/w aqueous solution during wet massing.
- composition of the aqueous Eudragit L3013-55 dispersion applied to the clarithromycin matrix pellets is provided below in Table 7.
- composition of the aqueous Eudragit® S 100 dispersion applied to the clarithromycin matrix pellets is provided below in Table 8.
- Eudragit ® S 100 Aqueous Coating Dispersion Component Percentage (%) Part A Eudragit ® S 100 10.0 1N Ammonium Hydroxide 5.1 Triethyl Citrate 5.0 Water 64.9 Part B Talc 5.0 Water 10.0 Solid Content 25.0 Polymer Content 10.0
- the following coating parameters were used for coating the matrix pellets with each of the Eudragit® L 30 D-55 and Eudragit® S 100 aqueous film coating.
- Coating Equipment STREA 1 TM Table Top Laboratory Fluid Bed Coater Spray nozzle diameter 1.0 mm Material Charge 300 gram Inlet Air Temperature 40 to 45° C. Outlet Air Temperature 30 to 33° C. Atomization Air Pressure 1.6 Bar Pump Rate 2 gram per minute
- enteric coating solution mix L30D and TEC for 30 minutes at low speed using an overhead mixer, according to Table 2.
- mix water and talc stirring vigorously.
- Sieve through 60 mesh screen prior to coating process. Keep stirring the dispersion at slow speed throughout the coating process.
- Coat tablets in a pan coater at 55° C. inlet temperature, 25 cfm air flow, pump setting of 7-10, pan speed 19 rpm, and atomization pressure of 25-26 psi. Up to 8% weight gain is desired for this coating procedure.
- a solution of 7% opadry solution in water is prepared by stirring.
- the coating is applied at inlet temp of 65° C., airflow 25 cfm, pump setting 8-9, pan speed 19 rpm, and 25 psi atomization air pressure to reach a total weight gain of 3-3.5%.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.
Description
- This invention relates to a pharmaceutical composition in tablet form that provides for both immediate and enteric release of an active drug agent, and also relates to the use and formulation of such pharmaceutical composition. More particularly, the present invention relates to a drug delivery system, in tablet form, that is comprised of an immediate release portion and a delayed release portion.
- In accordance with the invention an immediate release portion of the pharmaceutical composition contains an active ingredient, from which portion the initiation of release of said active agent is not substantially delayed after ingestion of the pharmaceutical composition.
- In accordance with the invention a delayed release portion of the pharmaceutical composition contains an active ingredient, from which portion the initiation of release of said active agent is substantially delayed after ingestion of the pharmaceutical composition.
- It is an aspect of the invention that the delayed release portion comprises an enteric coated layer, within which enteric coated layer there is a core tablet containing at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric coated minitablet dosage forms containing an active ingredient.
- In accordance with one aspect of the invention there is provided a delayed release portion that comprises a core tablet that includes an enteric coating, such that the core tablet does not disintegrate in the stomach; i.e., the core tablet disintegrates in the intestine. In accordance with a further aspect of the invention there is provided an immediate release portion whereby the enteric coated core tablet has a non-enteric coating over all or a portion of the enteric coating and this non-enteric coating provides for an immediate release of active that is contained therein; i.e., the immediate release portion releases active ingredient in the stomach.
- The core tablet includes therein particles and/or mini-tablets (“mini-tabs”) that include therein an active agent and that have an enteric coating to thereby delay release of active agent from the particles and/or mini-tablets until a time that is subsequent to the disintegration of the core tablet in the intestine. Additionally, the core tablet may or may not include a dosage of uncoated active ingredient the release of which is initiated at the time that the core tablet disintegrates in the intestine.
- In a preferred embodiment of the invention the core tablet, whether comprised of enteric-coated microparticles, enteric-coated mini-tabs, uncoated active ingredient, or combinations of the foregoing, is itself enteric-coated thereby to ensure its disintegration in the post-stomach GI tract.
- In an alternative embodiment of the invention the matrix of the core tablet includes enteric materials that maintain the structure of the core tablet to thereby ensure its disintegration in the post-stomach GI tract, whereby coating the core tablet with an enteric coating is not necessary, though is still preferred.
- It is to be understood that when it is disclosed herein that a dosage form initiates release after another dosage form, such terminology means that the dosage form is designed to produce, and is intended to produce, such later initiated release. It is known in the art, however, notwithstanding such design and intent, that some “leakage” of active ingredient may occur owing to known imperfections incident to current pharmaceutical manufacturing processes. Such “leakage” whether by flaking, chipping, or other means is not “release” as used herein.
- The core tablet may be either, a multiparticulate core: containing one or more pellet types, designed to release drug in the post-stomach portions of the GI tract, wherein the pellet types provide about 1 to 95% of total core tablet weight; or a mini-tab core: containing one or more mini-tabs also designed to release drug in the post-stomach GI tract, wherein the mm-tabs provide about 1 to 95% of total core tablet weight. The enteric polymer layer can be produced by spraying a number of different types of enteric polymers on top of the above-described core tablet. Thus, the enteric polymer coating delays the disintegration of the core tablet until the core tablet reaches the intestine. Additionally, the multiparticulates or mini-tabs comprising the core tablet may be formulated with further delayed and/or modified release materials, to thereby further delay and/or modify release of the active drug agents released therefrom.
- In one embodiment the immediate release portion may be an immediate release drug layer that can be sprayed on top of the enteric-coated core tablet to thereby serve as an immediate releasing portion of the drug delivery system.
- In one embodiment of the invention the immediate release drug layer completely engulfs the enteric polymer coated core tablet.
- In one embodiment of the invention the immediate release drug layer does not completely engulf the enteric polymer coating of the core tablet; in this embodiment a portion of the enteric polymer coating is exposed.
- In another embodiment of the invention the immediate release portion may comprise one layer of a bi-layer tablet in conjunction with the enteric-coated core tablet, or the immediate release portion may comprise a plurality of layers in a multi-layer tablet in conjunction with the enteric-coated core tablet.
- The instant invention is also directed to a process for treating a patient in need of treatment with an active medicinal agent, which comprises administering to the patient the hereinabove and hereinbelow described pharmaceutical compositions containing such an active medicinal agent.
- The instant invention is also directed to a method of making the hereinabove and hereinbelow described pharmaceutical compositions.
- Although most enteric coatings are generally known in the art to be pH-sensitive coatings, as used herein the term “enteric coating” includes both coatings that are pH-sensitive and coatings that are pH-independent. More particularly the term “enteric coating” as used herein indicates that the coating is one that is selected for its ability to deliver active ingredients to the post-stomach GI tract.
- As used herein the term “enteric coated tablet” means a tablet that is capable of delivering one or more pulses of active drug agent into the small intestinal region of the GI tract. Such enteric coated tablet is not limited to tablets engulfed by, or overlayed with, an enteric coating, but includes tablets having matrices comprising enteric materials that maintain the unit integrity of the core tablet at least until such tablet is delivered to the intestine. The core tablet of the instant invention is an enteric coated tablet in that it permits the delivery of a multi-particulate comprised (mini-tab, bead, microparticle, etc.) tablet into the GI tract as an intact unit. It is a beneficial aspect of the invention that the core tablet is passed from the stomach to the intestine substantially intact and that the core tablet does not disintegrate in the stomach.
- Generally, in those embodiments wherein the core tablet contains mini-tabs of the desired drug agent, those mini-tabs are formulated so that they are small enough to fit into a standard sized tablet core. The mini-tabs can be coated with an enteric coating that is either a delayed release and/or modified release coating. In a preferred embodiment the mini-tabs are coated with a delayed release coating. In another preferred embodiment there is a plurality of different mini-tabs in that each is coated with a delayed release coating that results in each different mini-tab initiating release of active ingredient therefrom at different times, each of which different times is subsequent to the time at which the core tablet enters the small intestine. Depending on the size of the mini-tabs, a core tablet may comprise one or more mini-tabs each consisting of the same drug agent or different drug agents, along with known pharmaceutical fillers. The core tablet is thereafter coated with an enteric coating that is either a delayed release or a modified release coating. The immediate release portion containing an active drug agent may thereafter be layered over at least a portion of the enteric-coated core tablet to provide an immediate release of a desired active drug agent.
- In one embodiment additional enteric materials are used to formulate the matrix of the above-described tablet core to thereby further modify release of active ingredient therefrom. In this embodiment an enteric polymer is sprayed on top of the core tablet, wherein enteric materials are used in formulating the matrix of the tablet core.
- In one embodiment additional enteric materials are used to formulate the beads or mini-tabs of the above-described tablet core to thereby further modify release of active ingredient therefrom. In this embodiment an enteric polymer is sprayed on top of the core tablet, wherein enteric materials are used in formulating the beads or mini-tabs of the tablet core.
- In one embodiment the core tablet comprises at least one mini-tab and an uncoated dosage of active ingredient, whereby after the core tablet's disintegration in the small intestine the uncoated dosage of active ingredient is immediately released at a first time and thereafter the at least one mini-tab initiates release of the active ingredient contained therein at a second time that is subsequent to said first time. This embodiment delivers at least three separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the uncoated dosage of active ingredient and the at least one mini-tab deliver later-initiated pulses in the intestine, whereby the initiation of release of active ingredient from the at least one mini-tab is subsequent to the initiation of release of active ingredient from the uncoated dosage of active ingredient.
- In one preferred embodiment the core tablet comprises at least two different mini-tabs, whereby after the core tablet's disintegration in the small intestine the first of the at least two different mini-tabs initiates release of the active ingredient contained therein at a first time, and the second of the at least two different mini-tabs initiates release of the active ingredient contained therein at a second time that is subsequent to said first time. This embodiment delivers at least three separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the at least two different mini-tabs deliver later-initiated pulses in the intestine, whereby the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab.
- In one embodiment the core tablet comprises at least two mini-tabs and an uncoated dosage of active ingredient, whereby after the core tablet's disintegration in the small intestine the uncoated dosage of active ingredient is immediately released at a first time and thereafter the at least two mini-tabs initiate release of the active ingredients contained therein at second and third times that are each subsequent to said first time. This embodiment delivers at least four separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the uncoated dosage of active ingredient and the at least two mini-tabs deliver later-initiated pulses in the intestine, whereby, the initiation of release of active ingredient from the at least two mini-tabs is subsequent to the initiation of release of active ingredient from the uncoated dosage of active ingredient, and the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab.
- In another preferred embodiment the core tablet comprises at least three different mini-tabs, whereby after the core tablet's disintegration in the small intestine the first of the at least three different mini-tabs initiates release of the active ingredient contained therein at a first time, the second of the at least three different mini-tabs initiates release of the active ingredient contained therein at a second time that is subsequent to said first time, and the third of the at least three different mini-tabs initiates release of the active ingredient contained therein at a third time that is subsequent to said second time. This embodiment delivers at least four separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the at least three different mini-tabs deliver later-initiated pulses in the intestine, whereby the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab, and the initiation of release of active ingredient from the third mini-tab is subsequent to the initiation of release of active ingredient from the second mini-tab.
- In one embodiment the core tablet comprises at least three mini-tabs and an uncoated dosage of active ingredient, whereby after the core tablet's disintegration in the small intestine the uncoated dosage of active ingredient is immediately released at a first time and thereafter the at least three mini-tabs initiate release of the active ingredients contained therein at second, third, and fourth times that are each subsequent to said first time. This embodiment delivers at least five separate pulses of active ingredient in that the immediate release portion delivers a first pulse in the stomach, and the uncoated dosage of active ingredient and the at least three mini-tabs deliver later-initiated pulses in the intestine whereby, the initiation of release of active ingredient from first of the at least three mini-tab is subsequent to the initiation of release of active ingredient from the uncoated dosage of active ingredient, the initiation of release of active ingredient from the second mini-tab is subsequent to the initiation of release of active ingredient from the first mini-tab, and the initiation of release of active ingredient from the third mini-tab is subsequent to the initiation of release of active ingredient from the second mini-tab.
- The present invention may be used to decrease the variability of the absorption of any active drug agent, and it is particularly useful for decreasing the absorption variability of antibiotics. The invention is more particularly useful for decreasing the absorption variability of beta-lactam antibiotics, cephalosporin antibiotics, and macrolide antibiotics. Even more particularly, it is useful for decreasing the absorption variabilities of amoxicillin and clarithromycin, both in separate formulations, and in formulations that combine amoxicillin and clarithromycin.
- Current multi-particulate and mini-tab tablet delivery systems, as applied to anti-infective agents, cannot prevent the pre-intestinal separation of microparticles or mini-tabs released in the stomach. These components generally exit the stomach through the pyloric valve or by the gastric emptying mechanisms of the stomach. In addition, the current tablet delivery systems are not staged, in other words they typically either dump the entire contents of the core tablet from the stomach into the small intestine as soon as the enteric coating is released, or they comprise a dosage form designed to give steady blood levels, as opposed to pulsatile blood levels, as soon as the enteric coating is released. This dumping of pellets into the stomach, inherent in the current state multi-particulate tablet dosage forms, can lead to pellet spread and a decrease in the strength of the pulses, resulting in significant variations in in vivo pharmacokinetics. Those variations can be expressed in any or all of Cmax, Tmax, Lag Time, and AUC. The dumping can also lead to local site concentration dilution. The present invention avoids these problems through a pulsatile dosing profile, whereby the drug is released in the GI tract in a staged manner, creating an increase and decrease in plasma levels over time. By including multi-particulate and mini-tab components in the core tablet system, these components can be engineered to release drag in a staged, or sequential burst, fashion to achieve pulsatile plasma levels such as are described in U.S. Pat. Nos. 6,544,555 and 6,723,341, the disclosures of which are hereby incorporated in their entireties.
- The enteric-coated core tablet of the present invention is large enough that it does not pass through the pyloric sphincter until after the pyloric sphincter opens to discharge stomach contents into the small intestine. The size of the microparticulates or mini-tabs incorporated into the core tablet does not effect the performance of the product since they are enveloped in the core tablet/enteric coating system, that is emptied as a unit into the small intestine. Accordingly, the size of microparticles and mini-tabs that comprise the core tablet can be relatively small in comparison to the core tablet. By grouping all the down stream pulses together in a core tablet and applying an enteric coating over the core tablet so that they remain bundled together while in the stomach the present invention overcomes the earlier-discussed dumping problems. This allows the pellets or mini-tabs to enter the small intestine as a single bulk unit, thereby avoiding the gradual gastric emptying effects that plague the current art. By creating an outer drug layer an immediate release pulse is also provided.
- The benefits of the present invention are not limited to a reduction of in vivo pharmacokinetic variabilities. The instant dual phase delivery paradigm is capable of facilitating high dose loading of a desired drug, and may deliver multiple pulses thereof. Additionally, the instant invention can deliver multiple drugs within the same dosing unit. This multi-dosing aspect allows the instant invention to deliver incompatible drug substances from the same tablet core. It also ensures that the delivery of one drug substance, or pulse of a drug substance, is not delivered until the desired previous substance, or pulse of a drug substance is delivered. The tablet of the present invention can also be used to deliver drugs that may be incompatible in the same dosage form, but which, when presented to the small intestine in combination via the core tablet, will work in tandem with respect to improving absorption or combating specific infectious problems. The instant invention also allows different regions of the GI tract to be specifically targeted for delivery. Also, the invention allows for once-a-day dosing to better ensure patient compliance; this avoids the possibility of overdosing the patient as only a portion of the drug is delivered at any time during the day. Furthermore, the instant invention permits for a smaller tablet size than can be achieved by way of more traditional multi-particulate tablets. In the more traditional multiparticulate tablets the pellets present greater surface area owing to the different functional coatings and different amounts of functional coatings that are applied to the pellets to create the pulsatile release in the GI tract. The traditional microparticulate tablet size is increased further still by the additions of the various fillers that hold the coated pellets together. In the traditional multiparticulate tablet models, much of the volume is occupied by the high polymer content of the individual pellets. In the instant invention, the first pulse is a coated layer on the surface of the enteric-coated core tablet, and the second pulse may be provided by the granulation inside the enteric coated core tablet that may also function as a cushioning agent or binder to hold the third pulse pellets together. Thus, the present invention provides a tablet in which the earlier pulses are concentrated and more dense, thereby presenting less surface area, and hence occupying less volume, in the tablet. Moreover, the instant drug delivery system allows the formulator to engineer pulses that release at any desired time.
- The core tablet of the present invention contains an active drug agent in the form of a prepared compactable matrix and/or compacted pellet, bead, or mini-tab. The pharmaceutical active agent is contained within the enteric-coated core tablet for modified delivery, and a drug layer on top of the enteric-coated tablet provides immediate release delivery. By delivering two or more releases of an active drug agent along the GI tract in a pulsatile fashion the instant improvement may be formulated to comport with the Pulsys™ technology. The Pulsys™ technology (which provides for distinct pulsatile releases of active ingredient separated in time) is described at length in U.S. Pat. No. 6,544,555 B2, issued to Rudnic et al.; the disclosures of which are hereby incorporated, by this reference, in their entireties. Like the Pulsys™ technology, the dual phase delivery system of the instant invention provides distinctly discernible pharmacokinetic curves at specific points in time for each of the delivered pulses of active ingredient.
- The core tablet may comprise of either or both of a multiparticulate active (pellet or bead) and/or a compressible active granule and/or matrix and/or mini-tab. A matrix could be made up of an active ingredient with enhancers to improve bioavailability or solubility of the active ingredient depending on limitations inherent to the particular active ingredient absorption characteristics. Active ingredient absorption limitations might be influenced by any or all of moisture content, pH, or active transport mechanisms. A typical pellet or multiparticulate active must be “robust” in that it must be capable of withstanding downstream processing activities. These processing operations may include, but are not limited to: wet granulation, extrusion, spheronization, fluid bed drying, fluid bed coating, roller compaction, tablet compression forces, and pan coating.
- While the examples and preferred embodiments of the present invention will describe its exceptional utility with regard to antibiotics, the disclosures herein conceive of their application to myriad other active drug agents. Non-limiting examples of such myriad other active drug agents include other anti-infective agents such as the antifungals and the antivirals, and antineoplastic agents.
- A wide variety of antibiotics have been used, and will be used, in order to combat bacterial infection. In general, such antibiotics can be administered by a repeated dosing of immediate release dosage forms, which results in poor compliance, or as controlled release formulations (slow release) at higher administered doses. In one embodiment the present invention is directed to providing for an improved antibiotic product.
- In accordance with one aspect of the dual phase delivery system of the present invention, there is provided an antibiotic pharmaceutical product, as described hereinabove and hereinbelow, which contains at least two, preferably at least three, antibiotic dosage forms. Such dosage forms are formulated so that each of the dosage forms has a different release profile.
- In a particularly preferred embodiment, there are at least two, preferably at least three dosage forms, each of which has a different release profile and the release profile of each of the dosage forms is such that the dosage forms each start release of the antibiotic contained therein at different times after administration of the antibiotic product.
- Thus, in accordance with an aspect of the present invention, there is provided a single or unitary antibiotic product that has contained therein at least two, preferably at least three antibiotic dosage forms, each of which has a different release profile, whereby the antibiotic contained in each of such dosage forms is released at different times.
- In accordance with a further aspect of the invention, the antibiotic product may be comprised of at least four different dosage forms, each of which starts to release the antibiotic contained therein at different times after administration of the antibiotic product.
- The antibiotic product generally does not include more than five dosage forms different release times.
- In accordance with a preferred embodiment, the antibiotic product has an overall release profile such that when administered the maximum serum concentration of the total antibiotic released from the product is reached in less than twelve hours, preferably in less than eleven hours. In an embodiment, the maximum serum concentration of the total antibiotic released from the antibiotic product is achieved no earlier than four hours after administration.
- In accordance with one preferred embodiment of the invention, there are at least two dosage forms. One of the at least two dosage forms is an immediate release dosage form whereby initiation of release of the antibiotic therefrom is not substantially delayed after administration of the antibiotic product. The second of the at least two dosage forms is an enteric dosage form, whereby the antibiotic released therefrom is delayed until after initiation of release of the antibiotic from the immediate release dosage form, and is further delayed until after the second dosage form (contained in the core tablet) has passed through the pyloric sphincter of the stomach and into the intestinal portion of the GI tract. More particularly, the antibiotic released from the second of the at least two dosage forms achieves a Cmax (maximum serum concentration in the serum) at a time after the antibiotic released from the first of the at least two dosage forms achieves a Cmax in the serum.
- In accordance with another preferred embodiment of the invention, there are at least three dosage forms. One of the at least three dosage forms is an immediate release dosage form whereby initiation of release of the antibiotic therefrom is not substantially delayed after administration of the antibiotic product. The second and third of the at least three dosage forms are enteric dosage forms, whereby the antibiotic released therefrom is delayed until after initiation of release of the antibiotic from the immediate release dosage form and is further delayed until after the second and third dosage forms (contained in the core tablet) have passed through the pyloric sphincter of the stomach and into the intestinal portion of the GI tract. More particularly, the antibiotic released from the second of the at least three dosage forms achieves a Cmax (maximum serum concentration in the serum) at a time after the antibiotic released from the first of the at least three dosage forms achieves a Cmax in the serum, and the antibiotic released from the third dosage form achieves a Cmax in the serum after the Cmax of antibiotic released from the second dosage form.
- In accordance with another preferred embodiment of the invention, the antibiotic is a beta-lactam antibiotic, a cephalosporin antibiotic, or a macrolide antibiotic.
- In accordance with another preferred embodiment of the invention, the antibiotic is amoxicillin.
- In accordance with another preferred embodiment of the invention, the antibiotic is clarithromycin.
- In accordance with another preferred embodiment of the invention, the tablet contains both amoxicillin and clarithromycin.
- In a more preferred embodiment of the invention, the antibiotic is amoxicillin and the compliment of amoxicillin released from each subsequently releasing dosage form expresses a maximum concentration in the serum that is equal to or exceeds the maximum concentration in the serum that is expressed by the compliment of amoxicillin released by the dosage form immediately preceeding that subsequently-releasing dosage form.
- In one embodiment, the second of the at least three dosage forms initiates release of the antibiotic contained therein at least one hour after the first dosage form, with the initiation of the release therefrom generally occurring no more than six hours after initiation of release of antibiotic from the first dosage form of the at least three dosage forms.
- In general, when three dosage forms are used, the immediate release dosage form produces a Cmax for the antibiotic released therefrom within from about 0.5 to about 2 hours, with the second dosage form of the at least three dosage forms producing a Cmax for the antibiotic released therefrom within about 6 hours. In general, the Cmax for such second dosage form is achieved no earlier than two hours after administration of the antibiotic product; however, it is possible within the scope of the invention to achieve Cmax in a shorter period of time.
- As hereinabove indicated, the antibiotic product may contain at least three or at least four or more different dosage forms. For example, if the antibiotic product includes a third dosage form, the antibiotic released therefrom reaches a Cmax at a time later than the Cmax is achieved for the antibiotic released from each of the first and second dosage forms. In a preferred embodiment, release of antibiotic from the third dosage form is started after initiation of release of antibiotic from both the first dosage form and the second dosage form. In one embodiment, Cmax for antibiotic release from the third dosage form is achieved within eight hours.
- In another embodiment, the antibiotic product contains at least four dosage forms, with each of the at least four dosage forms having different release profiles, whereby the antibiotic released from each of the at least four different dosage forms achieves a Cmax at a different time.
- As hereinabove indicated, in a preferred embodiment, irrespective of whether the antibiotic contains at least two or at least three or at least four different dosage forms each with a different release profile, Cmax for all the antibiotic released from the antibiotic product is achieved in less than twelve hours, and more generally is achieved in less than eleven hours.
- In a preferred embodiment, the antibiotic product is a once a day product, whereby after administration of the antibiotic product, no further product is administered during the day; i.e., the preferred regimen is that the product is administered only once over a twenty-four hour period. Thus, in accordance with the present invention, there is a single administration of an antibiotic product with the antibiotic being released in a manner such that overall antibiotic release is effected with different release profiles in a manner such that the overall Cmax for the antibiotic product is reached in less than twelve hours. The term single administration means that the total antibiotic administered over a twenty-four hour period is administered at the same time, which can be a single tablet or two or more thereof, provided that they are administered at essentially the same time.
- Applicant has found that a single dosage antibiotic product comprised of at least three antibiotic dosage forms each having a different release profile is an improvement over a single dosage antibiotic product comprised of an antibiotic dosage form having a single release profile. Each of the dosage forms of antibiotic in a pharmaceutically acceptable carrier may have one or more antibiotics and each of the dosage forms may have the same antibiotic or different antibiotics.
- Notwithstanding that the preferred embodiment is a once-a-day product the dual phase delivery system herein described is not restricted thereto, and may also be used for twice-a-day administration of drugs that have more limited windows of absorption.
- If at least four dosage forms are used, the fourth of the at least four dosage form may be a sustained release dosage form or a delayed release dosage form. If the fourth dosage form is a sustained release dosage form, even though Cmax of the fourth dosage form of the at least four dosage forms is reached after the Cmax of each of the other dosage forms is reached, antibiotic release from such fourth dosage form may be initiated prior to or after release from the second or third dosage form.
- The antibiotic product of the present invention is formulated in a manner such that it is suitable for oral administration.
- Alternatively, in formulating an oral delivery capsule system, several tablets may be put into a capsule to produce a unitary antibiotic product.
- In formulating an antibiotic product in accordance with the invention, in one embodiment, the immediate release drug layer of the product sprayed onto the enteric coated core tablet generally provides from about 5% to about 85% of the total dosage of antibiotic to be delivered by the product, with such immediate release drug layer generally providing at least 30-40% of the total dosage of the antibiotic to be delivered by the product. In many cases, the immediate release drug layer provides from about 30% to about 40% of the total dosage of antibiotic to be delivered by the product; however, in some cases it may be desirable to have the immediate release drug layer provide for about 5% to about 20% or 75% to about 85% of the total dosage of antibiotic to be delivered by the product.
- The remaining dosage forms deliver the remainder of the antibiotic. If more than one delayed release dosage form is used, in one embodiment, each of the delayed release dosage forms may provide about equal amounts of antibiotic; however, they may also be formulated so as to provide different amounts.
- In accordance with one embodiment of the present invention, each of the dosage forms may contain the same antibiotic. In accordance with one embodiment of the present invention, each of the dosage forms may contain different antibiotics. In accordance with one embodiment of the present invention each of the dosage forms may contain more than one antibiotic.
- In one embodiment, where the composition contains one immediate release component and two delayed release components, the immediate release component provides from 5% to 85% (preferably 30% to 40%), by weight, of the total antibiotic; where there are three delayed release components, the immediate release component provides from 5% to 75%, by weight, of the total antibiotic; and where there are four delayed release components, the immediate release component provides from 5% to 70%, by weight, of the total antibiotic.
- With respect to the delayed release components, where there are two delayed release components, the first delayed release component (the one released earlier in time) provides from 5% to 75%, by weight, of the total antibiotic provided by the two delayed release components with the second delayed release component providing the remainder of the antibiotic.
- Where there are three delayed release components, the earliest released component provides 5% to 75% by weight of the total antibiotic provided by the three delayed release components, the next in time delayed release component provides from 5% to 75%, by weight, of the antibiotic provided by the three delayed release components and the last in time providing the remainder of the antibiotic provided by the three delayed release components.
- When there are four delayed release components, the earliest delayed release component provides from 5% to 75%, by weight, the next in time delayed release component provides from 5% to 75%, by weight, the next in time delayed release component provides from 5% to 75%, by weight, and the last in time delayed release component provides from 5% to 75%, by weight, in each case of the total antibiotic provided by the four delayed release components.
- The materials to be added to the active ingredients for the immediate release component can be, but are not limited to, microcrystalline cellulose, corn starch, pregelatinized starch, potato starch, rice starch, sodium carboxymethyl starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose, chitosan, hydroxychitosan, hydroxymethylatedchitosan, cross-linked chitosan, cross-linked hydroxymethyl chitosan, maltodextrin, mannitol, sorbitol, dextrose, maltose, fructose, glucose, levulose, sucrose, polyvinylpyrrolidone (PVP), acrylic acid derivatives (Carbopol, Eudragit, etc.), polyethylene glycols, such a low molecular weight PEGs (PEG2000-10000) and high molecular weight PEGs (Polyox) with molecular weights above 20,000 daltons.
- In addition, it may be useful to have other ingredients in this system to aid in the dissolution of the drug, or the breakdown of the component after ingestion or administration. These ingredients can be surfactants, such as sodium lauryl sulfate, sodium monoglycerate, sorbitan monooleate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, glyceryl monostearate, glyceryl monooleate, glyceryl monobutyrate, one of the non-ionic surfactants such as the Pluronic line of surfactants, or any other material with surface active properties, or any combination of the above.
- The components in this composition are the same immediate release unit, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- Materials that can be used to obtain a delay in release suitable for this component of the invention can be, but are not limited to, polyethylene glycol (PEG) with molecular weight above 4,000 daltons (Carbowax, Polyox), waxes such as white wax or bees wax, paraffin, acrylic acid derivatives (Eudragit), propylene glycol, and ethylcellulose.
- The components in this composition are the same as the immediate release component, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- The kind of materials useful for this purpose can be, but are not limited to, cellulose acetate phthalate, Eudragit L, and other phthalate salts of cellulose derivatives.
- The components in this composition are the same as the Immediate release component, but with additional polymers integrated into the composition, or as coatings over the pellet or granule.
- The kind of materials useful for this purpose can be, but are not limited to, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylcellulose, nitrocellulose, Eudragit R, and Eudragit RL, Carbopol, or polyethylene glycols with molecular weights in excess of 8,000 daltons.
- The following are non-limiting, representative examples of some antibiotics that may be used in the product of the invention: Cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephacelor, cephprozil, cephachine, cefamandole, cefonicid, ceforanide, cefuroxime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, cefinetazole, cefotetan, cefoxitin, loracarbef, imipenem, erythromycin (and erythromycin salts such as estolate, ethylsuccinate, gluceptate, lactobionate, stearate), azithromycin, clarithromycin, dirithromycin, troleandomycin, penicillin V, penicillin salts, and complexes, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, amoxicillin, amoxicillin and clavulanate potassium, ampicillin, bacampicillin, carbenicillin indanyl sodium (and other salts of carbenicillin) mezlocillin, piperacillin, piperacillin and taxobactam, ticarcillin, ticarcillin and clavulanate potassium, clindamycin, vancomycin, novobiocin, aminosalicylic acid, capreomycin, cycloserine, ethambutol HCl and other salts, ethionamide, and isoniazid, ciprofloxacin, levofloxacin, lomefloxacin, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, sulfacitine, sulfamerazine, sulfamethazine, sulfamethizole, sulfasalazine, sulfisoxazole, sulfapyrazine, sulfadiazine, sulfamethoxazole, sulfapyridine, metronidazole, methenamine, fosfomycin, nitrofurantoin, trimetoprim, clofazimine, co-triamoxazole, pentamidine, and trimetrexate.
- The following are non-limiting, representative examples of some antivirals that may be used in the product of the invention: Acyclovir, Amantadine, Amprenavir, Cidofovir, Delavirdine, Didanosine, Famciclovir, Foscarnet, Ganciclovir, Indinavir, Interferon, Lamivudine, Nelfinavir, Nevirapine, Palivizumab, Penciclovir, Ribavirin, Rimantadine, Ritonavir, Saquinavir, Stavudine, Trifluridine, Valacyclovir, Vidarabine, Zalcitabine, Zidovudine.
- The following are representative examples of some antifungals that may be used in the product of the invention: amphotericin B, flucytosine, fluconazole, griseofulvin, miconazole nitrate, terbinafine hydrochloride, ketoconazole, itraconazole, undecylenic acid and chloroxylenol, ciclopirox, clotrimazole, butenafine hydrochloride, nystatin, naftifine hydrochloride, oxiconazole nitrate, selenium sulfide, econazole nitrate, terconazole, butoconazole nitrate, carbol-fuchsin, clioquinol, methylrosaniline chloride, sodium thiosulfate, sulconazole nitrate, terbinafine hydrochloride, tioconazole, tolnaftate, undecylenic acid and undecylenate salts (calcium undecylenate, copper undecylenate, zinc undecylenate).
- Dissolve binder and liquid ingredients in water. Place solid ingredients into a high shear blender (e.g. Glatt) and mix at low impeller speed (300 rpm) for 1 minute. At an impeller speed of 300 rpm and a chopper speed of 2500 rpm, slowly add the prepared binder solution to the dry mix (3-5 minutes). Add additional water as necessary. Continue to mix for 30 sec. Discharge material and transfer to an extruder. Extrude the granulation with a dome extruder at 50-100 rpm through a 0.6-1 mm, or other appropriate, screen. Transfer the extrudate into a spheronizer. Spheronize at 610 rpm for 20-30 sec. Discharge pellets and transfer to a fluidbed dryer (FluidAir). Dry at 60° C. inlet temp and 200 air flow until the loss on drying (LOD) does not change any further (approx. 60 min). Cool down the pellets at 25° C. air temperature for approximately 15 minutes prior to discharge.
- Preparation of the coating solution. Dissolve sodium lauryl sulfate (SLS) and triethyl citrate (TEC) in water using an overhead mixer. Add polymer and mix for 30-45 ruin. Add Talc and mix for 30-45 min. Sieve dispersion across a 60 mesh screen prior to use. Continue mixing during the entire coating process in the fluidbed. Transfer the pellets to a pre-heated fluidbed dryer (FluidAir). Apply the coating solution to the pellets spraying at 60-65° C. inlet temp, 170-180 scfm air flow and 30 psi atomization air pressure up to 40% weight gain. Dry pellets at 50° C. and 10 psi for 10 minutes, and cool at 30° C. prior to discharge. Sieve the final product across 20-40 mesh. Yield is typically>95%.
- Dissolve binder in water. Place the active pharmaceutical ingredient into a high shear blender (e.g. Glatt). At impeller speed 300 rpm and chopper speed 2500 rpm, slowly add the binder solution (3-5 minutes). Add additional water if necessary. Continue to mix for 30 sec. Discharge material and transfer to a fluidbed dryer. Dry the granulation at 50° C. for 60 minutes. Mill through a Comil U10 at speed 50 using screen 7A040603122329B(1016)90. Dry in fluidbed for 30 minutes at 50° C. Sieve across a 20 mesh screen.
- Weigh the appropriate amount of pulse 3 and/or 4 pellets, pulse 2 granulation, and remaining tabletting excipients. Combine all components except Magnesium Stearate (lubricant) in a PK blender and mix for 5 minutes. Add the lubricant and mix for an additional 2 minutes. Compress the blend on a tablet press to an appropriate hardness.
- To prepare enteric coating solution mix L30D and TEC for 30 minutes at low speed using an overhead mixer. In a separate container, mix water and talc, stirring vigorously. Add Talc slurry to the polymer dispersion. Sieve through 60 mesh screen prior to coating process. Keep stirring the dispersion at slow speed throughout the coating process. Coat tablets in a pan coater (LCDS) at 55° C. inlet temperature, 25 cfm air flow, pump setting of 7-10, pan speed 19 rpm, and atomization pressure of 25-26 psi. Up to 8% weight gain is required for this coating procedure. Yields are typically>95%.
- Dissolve HPMC in cold water. Add Amoxicillin, stirring with overhead stirrer at medium speed. Use LCDS 20/30 to apply the coating at inlet temp of 55° C., airflow 24 cfm, pump setting 10-12, pan speed 19 rpm, and 25-28 psi atomization air pressure until the desired weight gain is reached.
- A solution of 7% opadry solution in water is prepared by stirring. The coating is applied at inlet temp of 65° C., airflow 25 cfm, pump setting 8-9, pan speed 19 rpm, and 25 psi atomization air pressure to reach a total weight gain of 3-3.5%.
-
-
Ingredient % Active Pharmaceutical Ingredient 85-95% Microcrystalline Cellulose 4-8% Povidone 1-5% PEG-35 Castor Oil 0.5-2% Water As needed -
-
Ingredient % Active Pharmaceutical Ingredient 1-15% Microcrystalline Cellulose 69-91% Povidone 3-6% PEG-35 Castor Oil 5-10% Water As needed
These immediate release pellets can also be coated with an enteric or modified release coating to deliver active ingredient to the required locations in the GI tract. -
-
Ingredient % Active Granule 5-15% Enteric Coated Pellets 55-75% Microcrystalline Cellulose 5-10% Povidone K30 1-5% Croscarmelose Sodium 1-5% Magnesium Stearate 1-3% -
Ingredient % Active Granule 20-25% Enteric Coated Pellets 40-50% Microcrystalline Cellulose 20-30% Povidone K30 1-8% Croscarmellose Sodium 1-5% Magnesium Stearate 1-2% -
Ingredient % Active Granule 30-40% Enteric Coated Pellets 1-15% Microcrystalline Cellulose 40-60% Povidone K30 1-5% Croscarmelose Sodium 1-5% Magnesium Stearate 1-3% -
Ingredient % W/W Drug Granules 7.50% Pulsatile Pellet 3 15.00% Pulsatile Pellet 4 15.00% SMCC 27.50% Lactose Monohydrate 27.50% PVP K30 3.00% Croscarmellose Na 3.00% Magnesium Stearate 1.00% -
Ingredient % W/W Drug Granules 7.50% Pulsatile Pellet 3 20.00% Pulsatile Pellet 4 20.00% SMCC 21.25% Lactose Monohydrate 21.25% PVP K30 5.00% Croscarmellose Na 4.00% Magnesium Stearate 1.00% -
Ingredient % W/W Drug Granules 7.50% Pulsatile Pellet 3 30.00% Pulsatile Pellet 4 30.00% SMCC 11.75% Lactose Monohydrate 11.75% PVP K30 5.00% Croscarmellose Na 4.00% Magnesium Stearate 1.00% - Any of the enteric or modified release coatings available can be used to layer the core tablet to provide intra-stomach protection thereof and prevent pre-intestinal emptying of the tablet contents. Enteric polymers include, but are not limited to polyethyl acrylate, methyl methacrylate, ethyl acrylate, and trimethylammonioethyl methacrylate chloride copolymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, ethylvinylacetate phthalate, polyvinylacetate phthalate, and carboxymethylethylcellulose. Tablet contents (i.e. active matrix/pellets) are encapsulated and protected from releasing before the targeted release point. The coating must withstand downstream processing from farther tablet compression forces and/or tablet coating operations. In-vivo, the enteric coating should protect the active contents as they pass through the upper GI tract and stomach until reaching the desired trigger point within the small or large intestine. This will ensure that all of the tablet contents will be emptied as a single packet at the target and prevent separation and dilution of the drug during transit.
-
-
Ingredient % Methacrylic Copolymer 20-60% Talc 1-30% Triethyl Citrate 1-20% Sodium Lauryl Sulfate 0.25-1.0% Water As needed -
Ingredient % W/W Eudragit L30D-55 50.00% Triethyl Citrate 2.00% Glycerol Mono-Stearate 2.00% Water 46.00% - The active pharmaceutical layer or drug layer is applied on top of the protected enteric coated core tablet. The active layer delivers the first pulse or immediate release.
-
Ingredient % Active 1-40% Hydroxypropylmethylcellulose 1-10% Water As needed -
Ingredient % W/W Metronidazole 20.00% HPMC (low viscosity) 5.00% Water 75.00% - Pellet Formulations for Subsequent Coating
- The composition of the Amoxicillin trihydrate matrix pellets provided in Table 1.
-
TABLE 1 Composition of Amoxicillin Matrix Pellets Component Percentage (%) Amoxicillin Trihydrate powder 92 Avicel PH 101 7.0 Hydroxypropyl methylcellulose, NF* 1.0 Total 100 *Hydroxypropyl methylcellulose was added as a 2.9% w/w aqueous solution during wet massing. - Preparation Procedure for Amoxicillin Matrix Pellets
-
- Blend Amoxicillin and Avicel® PH 101 using a low shear blender.
- Add the hydroxypropyl methylcellulose binder solution slowly into the powder blend under continuous mixing.
- Extrude the wet mass using an LCI Bench Top Granulator. The diameter of the screen of the Bench Top Granulator is 0.8 mm.
- Spheronize the extrudate using a QJ-230 Spheronizer using a small cross section plate.
- Dry the spheronized pellets at 60° C. using a fluid bed exhaust temperature reaches 40° C.
- Pellets between 20 and 40 Mesh were collected for further processing.
- Preparation of an Eudragit® L 30 D-55 Aqueous Coating Dispersion
- Dispersion Formulation
- The composition of the aqueous Eudragit L30D-55 dispersion applied to the amoxicillin matrix pellets is provided below in Table 2.
-
TABLE 2 Eudragit ® L 30 D-55 Aqueous Coating Dispersion Component Percentage (%) Eudragit ® L 30 D-55 41.6 Triethyl Citrate 2.5 Talc 5.0 Purified Water 50.9 Solids Content 20.0 Polymer Content 12.5 - Preparation Procedure for an Eudragit® L 30 D-55 Aqueous Dispersion
-
- Suspend triethyl citrate and talc in deionized water.
- The TEC/talc suspension is mixed using laboratory mixer.
- Add the TEC/talc suspension from slowly to the Eudragit® L 30 D-55 latex dispersion while stirring.
- Allow the coating dispersion to stir for one hour prior to application onto the amoxicillin matrix pellets.
- Preparation of an Eudragit® S 100 Aqueous Coating Dispersion
- Dispersion Formulation
- The composition of the aqueous Eudragit® S 100 dispersion applied to the Amoxicillin matrix pellets is provided below in Table 3.
-
TABLE 3 Eudragit ® S 100 Aqueous Coating Dispersion Component Percentage (%) Part A Eudragit ® S 100 10.0 1N Ammonium Hydroxide 5.1 Triethyl Citrate 5.0 Water 64.9 Part B Talc 5.0 Water 10.0 Solid Content 25.0 Polymer Content 10.0 - Preparation Procedure for an Eudragit® S 100 Aqueous Dispersion
- Part A:
-
- Dispense Eudragit® S 100 powder in deionized water with stirring.
- Add ammonium hydroxide solution drop-wise into the dispersion with stirring.
- Allow the partially neutralized dispersion to stir for 60 minutes.
- Add triethyl citrate drop-wise into the dispersion with stirring and let stir overnight prior to the addition of Part B.
- Part B:
-
- Disperse talc in the required amount of water
- Stir the dispersion using an overhead laboratory mixer.
- Part B is then added slowly to the polymer dispersion in Part A with a mild stirring.
- Coating Conditions for the Application of Aqueous Coating Dispersions
- The following coating parameters were used for both the Eudragit® L 30 D-55 and Eudragit® S 100 aqueous coating processes.
-
Coating Equipment STREA 1 ™ Table Top Laboratory Fluid Bed Coater Spray nozzle diameter 1.0 mm Material Charge 300 gram Inlet Air Temperature 40 to 45° C. Outlet Air Temperature 30 to 33° C. Atomization Air Pressure 1.8 Bar Pump Rate 2-6 gram per minute -
- Coat matrix pellets with L30 D-55 dispersion such that you apply 20% coat weight gain to the pellets.
- Coat matrix pellets with S100 dispersion such that you apply 37% coat weight gain to the pellets.
- Preparation of Amoxicillin Granulation (Immediate Release Component) for tabletting
-
TABLE 4 Composition of Amoxicillin Granulation Component Percentage (%) Amoxicillin Trihydrate powder 92 Avicel PH 101 7.0 Hydroxypropyl methylcellulose, NF* 1.0 Total 100 *Hydroxypropyl methylcellulose was added as a 2.9% w/w aqueous solution during wet massing. -
- Blend Amoxicillin and Avicel® PH 101 using a low shear blender.
- Add the hydroxypropyl methylcellulose binder solution slowly into the powder blend under continuous mixing.
- Dry the granulation at 60° C. using a fluid bed dryer until the exhaust temperature reaches 40° C.
- Granules between 20 and 40 Mesh are collected for further processing.
- Tabletting of the Amoxicillin Pellets
-
TABLE 5 Composition of Amoxicillin Tablets Component Percentage (%) Amoxicillin granules 32.5 Avicel PH 200 5.0 Amoxicillin L30D-55 coated pellets 30 Amoxicillin S100 coated pellets 30 Colloidal silicon dioxide 1.5 Magnesium stearate 1.0 Total 100 -
- Blend the Amoxicillin granules, Avicel PH-200, Amoxicillin pellets and colloidal silicon dioxide for 15 minutes in a tumble blender.
- Add the magnesium stearate to the blender, and blend for 5 minutes.
- Compress the blend on a rotary tablet press.
- The fill weight should be adjusted to achieve a 500 mg dose tablet.
- General Procedure for Enteric Coating of Tablets
- To prepare enteric coating solution mix L30D and TEC for 30 minutes at low speed using an overhead mixer, according to Table 2. In a separate container, mix water and talc, stirring vigorously. Add Talc slurry to the polymer dispersion. Sieve through 60 mesh screen prior to coating process. Keep stirring the dispersion at slow speed throughout the coating process.
- Coat tablets in a pan coater (LCDS) at 55° C. inlet temperature, 25 cfm air flow, pump setting of 7-10, pan speed 19 rpm, and atomization pressure of 25-26 psi. Up to 8% weight gain is desired for this coating procedure.
-
Coating Equipment LCDS laboratory Pan Coater pan speed 19 rpm atomization pressure of 25-26 psi Inlet Air Temperature 50-60° C. Outlet Air Temperature 30 to 33° C. Pump Rate 7-10 gram per minute - General Procedure for Applying Immediate Release Active Coating
-
- Dissolve HPMC in cold water. Add Amoxicillin, stirring with overhead stirrer at medium speed. Use LCDS 20/30 to apply the coating at inlet temp of 55° C., airflow 24 cfm, pump setting 10-12, pan speed 19 rpm, and 25-28 psi atomization air pressure until the desired weight gain is reached.
- General Procedure for Optional
- Immediate Release Cosmetic/Taste Masking Coating
- A solution of 7% opadry solution in water is prepared by stirring. The coating is applied at inlet temp of 65° C., airflow 25 cfm, pump setting 8-9, pan speed 19 rpm, and 25 psi atomization air pressure to reach a total weight gain of 3-3.5%.
- This example makes a complete amoxicillin enteric coated tablet with 4 pulses containing 500-800 mg amoxicillin.
- Clarithromycin Pellet Formulation and Preparation Procedure
- Pellet Formulation
- The composition of the clarithromycin matrix pellets provided in Table 6.
-
TABLE 6 Composition of Clarithromycin Pellets Component Percentage (%) Clarithromycin 50.6 Lactose monohydrate, spray dried 32.1 Silicified microcrystalline cellulose 14.6 Polyoxyl 35 Castor Oil* 1.7 Hydroxypropyl methylcellulose* 1.0 Total 100 *Hydroxypropyl methylcellulose and Polyoxyl 35 were added as an 8.7% w/w aqueous solution during wet massing. - Preparation Procedure for Clarithromycin Matrix Pellets
-
- Blend clarithromycin, silicified microcrystalline cellulose and lactose monohydrate using a Robot Coupe high shear granulator.
- Prepare the binder solution by adding the Polyoxyl to the purified water while stirring. After that is mixed, slowly add the hydroxypropyl methylcellulose and continue to stir until a solution is achieved.
- Add binder solution slowly into the powder blend under continuous mixing.
- Granulate the powders in the high shear granulator with the binder solution.
- Extrude the wet mass using an LCI Bench Top Granulator. The diameter of the screen of the Bench Top Granulator was 1.2 mm.
- Spheronize the extrudate using a Model SPH20 Caleva Spheronizer.
- Dry the spheronized pellets at 50° C. overnight.
- Pellets between 18 and 30 Mesh were collected for further processing
- Preparation of an Eudragit® L 30 D-55 Aqueous Coating Dispersion
- Dispersion Formulation
- The composition of the aqueous Eudragit L3013-55 dispersion applied to the clarithromycin matrix pellets is provided below in Table 7.
-
TABLE 7 Eudragit ® L 30 D-55 Aqueous Coating Dispersion Component Percentage (%) Eudragit ® L 30 D-55 40.4 Triethyl Citrate 1.8 Talc 6.1 Water 51.7 Solids Content 20.0 Polymer Content 12.1 - Preparation Procedure for an Eudragit® L 30 D-55 Aqueous Dispersion
-
- Suspend triethyl citrate and talc in deionized water.
- The TEC/talc suspension is then homogenized using a PowerGen 700 high shear mixer.
- Add the suspension from 4.2.2 slowly to the Eudragit® L 30 D-55 latex dispersion while stirring.
- Allow the coating dispersion to stir for one hour prior to application onto the clarithromycin matrix pellets.
- Preparation of an Eudragit® S 100 Aqueous Coating Dispersion
- Dispersion Formulation
- The composition of the aqueous Eudragit® S 100 dispersion applied to the clarithromycin matrix pellets is provided below in Table 8.
-
TABLE 8 Eudragit ® S 100 Aqueous Coating Dispersion Component Percentage (%) Part A Eudragit ® S 100 10.0 1N Ammonium Hydroxide 5.1 Triethyl Citrate 5.0 Water 64.9 Part B Talc 5.0 Water 10.0 Solid Content 25.0 Polymer Content 10.0 - Preparation Procedure for an Eudragit® S 100 Aqueous Dispersion
- Part A:
-
- Dispense Eudragit® S 100 powder in deionized water with stirring.
- Add ammonium hydroxide solution drop-wise into the dispersion with stirring.
- Allow the partially neutralized dispersion to stir for 60 minutes
- Add the triethyl citrate drop-wise to the dispersion and stir for 6 minutes prior to the addition of Part B.
- Part B:
-
- Disperse talc in the required amount of water
- Homogenize the dispersion using a PowerGen 700D high shear mixer. Part B is then added slowly to the polymer dispersion in Part A with a mild stirring.
- Coating Conditions for the Application of Aqueous Coating Dispersions
- The following coating parameters were used for coating the matrix pellets with each of the Eudragit® L 30 D-55 and Eudragit® S 100 aqueous film coating.
-
Coating Equipment STREA 1 ™ Table Top Laboratory Fluid Bed Coater Spray nozzle diameter 1.0 mm Material Charge 300 gram Inlet Air Temperature 40 to 45° C. Outlet Air Temperature 30 to 33° C. Atomization Air Pressure 1.6 Bar Pump Rate 2 gram per minute -
- Coat matrix pellets With L30 D-55 dispersion such that you apply 20% coat weight gain to the pellets.
- Coat matrix pellets with S100 dispersion such that you apply 37% coat weight gain to the pellets.
- Preparation of Clarithromycin Granulation (Immediate Release Component) for Tabletting
-
TABLE 9 Composition of clarithromycin Granulation Component Percentage (%) clarithromycin powder 92 Avicel PH 101 7.0 Hydroxypropyl methylcellulose, NF* 1.0 Total 100 *Hydroxypropyl methylcellulose was added as a 2.9% w/w aqueous solution during wet massing. -
- Blend clarithromycin and Avicel® PH 101 using a low shear blender.
- Add the hydroxypropyl methylcellulose binder solution slowly into the powder blend under continuous mixing.
- Dry the granulation at 60° C. using a fluid bed dryer until the exhaust temperature reaches 40° C.
- Granules between 20 and 40 Mesh are collected for further processing.
- Tabletting of the Clarithromycin Pellets
-
TABLE 10 Composition of Clarithromycin Tablets Component Percentage (%) clarithromycin granules 32.5 Avicel PH 200 5.0 clarithromycin L30D-55 coated pellets 30 clarithromycin S100 coated pellets 30 Colloidal silicon dioxide 1.5 Magnesium stearate 1.0 Total 100 -
- Blend the clarithromycin granules, Avicel PH-200, clarithromycin pellets and colloidal silicon dioxide for 15 minutes in a tumble blender.
- Add the magnesium stearate to the blender, and blend for 5 minutes.
- Compress blend on a rotary tablet press.
- The fill weight should be adjusted to achieve a 500 mg dose tablet.
- General Procedure for Enteric Coating of Tablets
- To prepare enteric coating solution mix L30D and TEC for 30 minutes at low speed using an overhead mixer, according to Table 2. In a separate container, mix water and talc, stirring vigorously. Add Talc slurry to the polymer dispersion. Sieve through 60 mesh screen prior to coating process. Keep stirring the dispersion at slow speed throughout the coating process.
- Coat tablets in a pan coater (LCDS) at 55° C. inlet temperature, 25 cfm air flow, pump setting of 7-10, pan speed 19 rpm, and atomization pressure of 25-26 psi. Up to 8% weight gain is desired for this coating procedure.
-
Coating Equipment LCDS laboratory Pan Coater pan speed 19 rpm atomization pressure of 25-26 psi Inlet Air Temperature 50-60° C. Outlet Air Temperature 30 to 33° C. Pump Rate 7-10 gram per minute - General Procedure for Applying Immediate Release Active Coating
-
- Dissolve HPMC in cold water. Add clarithromycin, stirring with overhead stirrer at medium speed. Use LCDS 20/30 to apply the coating at inlet temp of 55° C., airflow 24 cfm, pump setting 10-12, pan speed 19 rpm, and 25-28 psi atomization air pressure until the desired weight gain is reached.
- General Procedure for Optional
- Immediate Release Cosmetic/Taste Masking Coating
- A solution of 7% opadry solution in water is prepared by stirring. The coating is applied at inlet temp of 65° C., airflow 25 cfm, pump setting 8-9, pan speed 19 rpm, and 25 psi atomization air pressure to reach a total weight gain of 3-3.5%.
- This makes a complete clarithromycin enteric coated tablet with 4 pulses.
Claims (21)
1. A pharmaceutical tablet, said tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein said delayed release portion comprises an enteric-coated layer and within said enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated minitablet dosage forms containing an active ingredient.
2. The pharmaceutical tablet of claim 1 , wherein said active ingredients consist of the same active ingredient.
3. The pharmaceutical tablet of claim 1 , wherein said active ingredients comprise at least two different active ingredients.
4. The pharmaceutical tablet of claim 1 , wherein said active ingredient is selected from the group consisting of antibiotics, antivirals, antifungals, and antineoplastics.
5. The pharmaceutical tablet of claim 4 , wherein said antibiotic is selected from the group consisting of beta-lactams, cephalosporins, and macrolides.
6. The pharmaceutical tablet of claim 3 , wherein said at least two different active ingredients comprise amoxicillin and clarithromycin.
7. The pharmaceutical tablet of claim 5 , wherein said beta-lactam antibiotic is amoxicillin.
8. The pharmaceutical tablet of claim 7 , wherein the compliment of amoxicillin released from each subsequently releasing dosage form expresses a maximum concentration in the serum that is equal to or exceeds the maximum concentration in the serum that is expressed by the compliment of amoxicillin released by the dosage form immediately preceding that subsequently-releasing dosage form.
9. A method for preparing a pharmaceutical tablet having an immediate release portion and a delayed release portion for immediate and delayed release delivery of at least one active ingredient, said method comprising the steps of: (a) formulating a delayed release portion that comprises a core tablet and an enteric coating, such that said core tablet comprises at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient; and such that said enteric coating covers said core tablet; and (b) applying an immediate release portion containing an active ingredient as an immediate release layer over said delayed release portion such that said immediate release layer at least partially covers said delayed release portion.
10. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 1 , once or twice, daily.
11. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 2 , once or twice, daily.
12. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 3 , once or twice, daily.
13. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 4 , once or twice, daily.
14. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 5 , once or twice, daily.
15. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 6 , once or twice, daily.
16. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 7 , once or twice, daily.
17. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet of claim 8 , once or twice, daily.
18. A process for treating a bacterial infection in a host comprising: administering to a host the pharmaceutical tablet produced by the method of claim 9 , once or twice, daily.
19. The pharmaceutical tablet of claim 1 , wherein said at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated minitablet dosage forms containing an active ingredient, is a pH-sensitive dosage form.
20. The pharmaceutical tablet of claim 1 , wherein said at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated minitablet dosage forms containing an active ingredient, is a pH-independent dosage form.
21.-22. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/228,817 US20140212490A1 (en) | 2004-07-02 | 2014-03-28 | Tablet for pulsed delivery |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58520204P | 2004-07-02 | 2004-07-02 | |
US11/173,929 US8715727B2 (en) | 2004-07-02 | 2005-07-01 | Tablet for pulsed delivery |
US14/228,817 US20140212490A1 (en) | 2004-07-02 | 2014-03-28 | Tablet for pulsed delivery |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/173,929 Continuation US8715727B2 (en) | 2004-07-02 | 2005-07-01 | Tablet for pulsed delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140212490A1 true US20140212490A1 (en) | 2014-07-31 |
Family
ID=35787406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/173,929 Active 2030-03-30 US8715727B2 (en) | 2004-07-02 | 2005-07-01 | Tablet for pulsed delivery |
US14/228,817 Abandoned US20140212490A1 (en) | 2004-07-02 | 2014-03-28 | Tablet for pulsed delivery |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/173,929 Active 2030-03-30 US8715727B2 (en) | 2004-07-02 | 2005-07-01 | Tablet for pulsed delivery |
Country Status (6)
Country | Link |
---|---|
US (2) | US8715727B2 (en) |
EP (1) | EP1771158A4 (en) |
JP (1) | JP2008505124A (en) |
AU (1) | AU2005269981A1 (en) |
CA (1) | CA2572292A1 (en) |
WO (1) | WO2006014427A1 (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070160675A1 (en) * | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
LT2502911T (en) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US9149439B2 (en) * | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
CN102775396B (en) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Modulators of ATP-binding cassette transporters |
AP3071A (en) * | 2005-11-28 | 2014-12-31 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the makingand use thereof |
US20080139526A1 (en) * | 2006-12-06 | 2008-06-12 | Donald Treacy | Modified release dosage forms of amoxicillin |
US8357394B2 (en) * | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
PT2674428T (en) | 2006-04-07 | 2016-07-14 | Vertex Pharma | Modulators of atp-binding cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8299052B2 (en) * | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
WO2008008120A1 (en) * | 2006-07-14 | 2008-01-17 | Fmc Corporation | Solid form |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
KR20090091321A (en) | 2006-11-28 | 2009-08-27 | 마리누스 파마슈티컬스 | Nanoparticulate formulations and methods for the making and use thereof |
DE102007009243A1 (en) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets with a drug matrix and a polymer coating, and a method for producing the pellets |
WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
WO2008140460A1 (en) * | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
WO2008140461A1 (en) * | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
US20080286344A1 (en) * | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
WO2008140459A1 (en) * | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
US20080286343A1 (en) * | 2007-05-16 | 2008-11-20 | Dzenana Cengic | Solid form |
EP2197448A4 (en) * | 2007-09-12 | 2010-11-17 | Elan Pharma Int Ltd | Dosing regimen |
ES2406940T3 (en) | 2007-12-07 | 2013-06-10 | Vertex Pharmaceuticals Incorporated | Procedures for producing cycloalkylcarboxyamido-pyridinebenzoic acids |
CN103626744B (en) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | The benzoic solid form of 3-(6-(1-(2,2-difluoro benzo [D] [1,3] dioxole-5-yl) cyclopropane formamido group)-3-picoline-2-yl) |
EP2271622B1 (en) | 2008-02-28 | 2017-10-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR Modulators |
ES2552723T3 (en) * | 2008-05-06 | 2015-12-01 | Dexcel Pharma Technologies Ltd. | Stable benzimidazole formulation |
US9320738B2 (en) | 2008-06-30 | 2016-04-26 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
AU2013205004B2 (en) * | 2008-06-30 | 2015-08-27 | Tocagen Inc. | Formulations of 5-fluorocytosine and Uses Thereof |
WO2010077061A2 (en) * | 2008-12-31 | 2010-07-08 | 한올바이오파마 주식회사 | Pharmaceutical formulations containing antiviral drugs |
JP5763046B2 (en) | 2009-03-20 | 2015-08-12 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Method for producing modulators of cystic fibrosis membrane conductance regulators |
WO2011025673A1 (en) * | 2009-08-26 | 2011-03-03 | Aptapharma, Inc. | Multilayer minitablets |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ708598A (en) | 2010-04-07 | 2017-05-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d](1,3)dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
WO2011133951A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
KR20190061096A (en) | 2010-04-22 | 2019-06-04 | 버텍스 파마슈티칼스 인코포레이티드 | Process of producing cycloalkylcarboxamido-indole compounds |
WO2013001543A1 (en) * | 2011-06-30 | 2013-01-03 | Aggarwal Kumar Vijay | An optimized bilayered tablet dosage form with two active antibiotics: clavulanic acid and cefpodoxime |
JP2015511583A (en) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Pharmaceutical composition and its administration |
EP2838517B1 (en) * | 2012-04-18 | 2017-10-18 | Contera Pharma APS | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2014033077A1 (en) | 2012-08-28 | 2014-03-06 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets |
WO2015073231A1 (en) | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
UA124567C2 (en) | 2014-04-15 | 2021-10-13 | Вертекс Фармасьютикалз Інкорпорейтед | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN103948555A (en) * | 2014-04-21 | 2014-07-30 | 海南海力制药有限公司 | Amoxicillin pulse sustained release tablet and preparation method thereof |
MX370450B (en) | 2014-10-07 | 2019-12-13 | Vertex Pharma | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator. |
PL3221692T3 (en) | 2014-11-18 | 2021-12-06 | Vertex Pharmaceuticals Inc. | Process of conducting high throughput testing high performance liquid chromatography |
CN105106133B (en) * | 2015-09-22 | 2018-02-06 | 四川省川龙动科药业有限公司 | A kind of rumen bypass coating Amoxicillin micropill and preparation method thereof |
JP7227896B2 (en) | 2016-07-11 | 2023-02-22 | コンテラ ファーマ エー/エス | Pulsatile drug delivery system for treating morning immobility |
EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
US11724486B2 (en) | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
CN114828889A (en) | 2019-12-06 | 2022-07-29 | 马瑞纳斯制药公司 | Ganaxolone for the treatment of tuberous sclerosis |
Family Cites Families (302)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3108046A (en) | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
NL123741C (en) * | 1962-09-05 | |||
US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4175125A (en) | 1971-12-27 | 1979-11-20 | Eli Lilly And Company | Method for treating methicillin resistant staphylococcus aureus |
GB1472534A (en) | 1973-07-06 | 1977-05-04 | Glaxo Lab Ltd | 7beta-hydroxyiminoacylamido-cephalosporins |
IE41109B1 (en) | 1974-04-20 | 1979-10-24 | Beecham Group Ltd | Novel -lactam antibiotic from streptomyces clavuligerus |
US4529720A (en) | 1974-04-20 | 1985-07-16 | Beecham Group, P.L.C. | Antibiotic from Streptomyces clavulicerus |
JPS5119765A (en) | 1974-08-09 | 1976-02-17 | Takeda Chemical Industries Ltd | Aminochiazoorujudotaino seizoho |
AT342770B (en) | 1975-04-07 | 1978-04-25 | Thomae Gmbh Dr K | PROCESS FOR PRODUCING NEW ERYTHROMYCINE DERIVATIVES |
US6218380B1 (en) | 1975-04-17 | 2001-04-17 | Smithkline Beecham P.L.C. | Pharmaceutical compositions |
US6031093C1 (en) | 1975-04-17 | 2001-10-16 | Smithkline Beecham Plc | Solid salts of clavulanic acid |
US4018918A (en) | 1975-05-20 | 1977-04-19 | The Upjohn Company | Topical clindamycin preparations |
US4131672A (en) | 1975-06-09 | 1978-12-26 | Eli Lilly And Company | Method for treating methicillin resistant Staphylococcus aureus |
US4250166A (en) | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
US4236211A (en) | 1978-09-15 | 1980-11-25 | Pfizer Inc. | Method and apparatus for determining the minimum concentration of antibiotic necessary to at least inhibit microorganism growth |
US4226849A (en) | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
FR2470599A1 (en) | 1979-12-07 | 1981-06-12 | Panoz Donald | IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED |
US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
US4399151A (en) | 1980-06-16 | 1983-08-16 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting the growth of protozoa |
US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
IL64009A (en) | 1980-10-31 | 1984-09-30 | Rech Applications Therap | Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them |
EP0052075A1 (en) | 1980-11-12 | 1982-05-19 | Ciba-Geigy Ag | Sustained release pharmaceutical granule |
SI8110592A8 (en) | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4435173A (en) | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
US4598045A (en) | 1982-08-25 | 1986-07-01 | Hana Biologics, Inc. | Triphasic mycoplasmatales detection method |
US4430495A (en) | 1982-09-17 | 1984-02-07 | The Upjohn Company | Process for preparing lincomycin and clindamycin ribonucleotides |
AU575854B2 (en) | 1983-10-04 | 1988-08-11 | Shionogi & Co., Ltd. | 7beta-(carboxyalkenamido) cephalosporins |
DE3405378A1 (en) | 1984-02-15 | 1985-08-22 | Röhm GmbH, 6100 Darmstadt | MEDICINE COVER |
JPS60214796A (en) | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | Growth hormone for fishes |
US4616008A (en) | 1984-05-02 | 1986-10-07 | Takeda Chemical Industries, Ltd. | Antibacterial solid composition for oral administration |
US4568741A (en) | 1984-05-15 | 1986-02-04 | The Upjohn Company | Synthesis of 7-halo-7-deoxylincomycins |
US4879135A (en) | 1984-07-23 | 1989-11-07 | University Of Medicine And Dentistry Of New Jersey | Drug bonded prosthesis and process for producing same |
JPS61103890A (en) | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | 6-o-methylerythromycin a derivative |
CN1004002B (en) | 1984-11-29 | 1989-04-26 | 厄普约翰公司 | Improving one's methods of preparation 7-halogen-7-deoxy-lincomycin and similar compound thereof |
EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
US4670549A (en) | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
US4894119A (en) | 1985-04-10 | 1990-01-16 | Drew Chemical Corporation | Retention and/or drainage and/or dewatering aid |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4775751A (en) | 1985-06-03 | 1988-10-04 | Eli Lilly & Company | Process for cephalexin hydrochloride alcoholates |
DE3524572A1 (en) | 1985-07-10 | 1987-01-15 | Thomae Gmbh Dr K | SOLID PHARMACEUTICAL FORMS FOR PERORAL USE CONTAINING 9-DEOXO-11-DEOXY-9,11- (IMINO (2- (2-METHOXYETHOXY) ETHYLIDEN) -OXY) - (9S) -ERYTHROMYCIN AND METHOD FOR THE PRODUCTION THEREOF |
FR2585948B1 (en) | 1985-08-06 | 1988-12-16 | Pf Medicament | PROCESS FOR THE MANUFACTURE OF INDOMETACIN TABLETS |
DE3684446D1 (en) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | MEDICINAL PRODUCTS WITH DELAYED RELEASED RELEASE. |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
LU87041A1 (en) | 1987-11-04 | 1989-06-14 | Oreal | RETINOIC ESTERS OF MACROLIDES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM |
US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
NZ220764A (en) | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
KR960000434B1 (en) | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | Eryhromycin a derivatives and process of method for the same |
US4749568A (en) | 1987-01-23 | 1988-06-07 | The Upjohn Company | Rubradirin treatment of methicillin-resistant staph |
US5200193A (en) | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
US4945405A (en) | 1987-05-21 | 1990-07-31 | Minolta Camera Kabushiki Kaisha | Color image read apparatus with shading and color balance correction |
US5143661A (en) | 1987-05-26 | 1992-09-01 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules |
US4945080A (en) | 1987-05-26 | 1990-07-31 | Eli Lilly And Company | Dirithromycin metabolite |
US4808411A (en) | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
US5110597A (en) | 1987-06-25 | 1992-05-05 | Alza Corporation | Multi-unit delivery system |
US4835140A (en) | 1987-08-20 | 1989-05-30 | Indiana University Foundation | Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine |
US4915953A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering acetaminophen or phenylpropanolamine |
US4971805A (en) | 1987-12-23 | 1990-11-20 | Teysan Pharmaceuticals Co., Ltd. | Slow-releasing granules and long acting mixed granules comprising the same |
JP2751385B2 (en) | 1988-05-19 | 1998-05-18 | 大正製薬株式会社 | Process for producing erythromycin A oxime and its salt |
US4895934A (en) | 1988-08-22 | 1990-01-23 | E. I. Du Pont De Nemours And Company | Process for the preparation of clindamycin phosphate |
US4849515A (en) | 1988-08-22 | 1989-07-18 | E. I. Du Pont De Nemours And Company | Clindamycin-2-phosphoryl benzylate |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5178874A (en) | 1989-06-30 | 1993-01-12 | Smithkline Beechman Corporation | Intermittent release dosage form |
US5110598A (en) | 1989-06-30 | 1992-05-05 | Smithkline Beecham Corp. | Intermittent release dosage form |
ATE114472T1 (en) | 1989-09-21 | 1994-12-15 | American Cyanamid Co | ''ONCE DAILY'' PULSED MINOCYCLINE DELIVERY SYSTEM. |
DK469989D0 (en) | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
US5204055A (en) | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US5387380A (en) | 1989-12-08 | 1995-02-07 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
JPH0674206B2 (en) | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | Controlled release formulation and process for producing |
US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5158777A (en) | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
US5358713A (en) | 1990-02-23 | 1994-10-25 | Mitsui Norin Co., Ltd. | Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus |
US5182374A (en) | 1990-03-21 | 1993-01-26 | American Cyanamid Company | Clindamycin phosphate synthesis |
GB2253346A (en) | 1991-02-22 | 1992-09-09 | John Rhodes | Delayed release oral dosage forms for treatment of intestinal disorders |
US5556839A (en) | 1991-04-29 | 1996-09-17 | Eli Lilly And Company | Form II Dirithromycin |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
MY113261A (en) | 1991-09-30 | 2002-01-31 | Lilly Co Eli | One step process for production of dirithromycin. |
US5334590A (en) | 1991-10-17 | 1994-08-02 | Merck & Co., Inc. | MRSA active 2-phenyl-carbapenems |
US5476854A (en) | 1991-11-27 | 1995-12-19 | Sepracor Inc. | Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin |
US5260066A (en) | 1992-01-16 | 1993-11-09 | Srchem Incorporated | Cryogel bandage containing therapeutic agent |
US6117843A (en) | 1992-02-18 | 2000-09-12 | Lloyd J. Baroody | Compositions for the treatment of acne containing clindamycin and benzoyl peroxide |
TW203552B (en) | 1992-02-18 | 1993-04-11 | J Baroody Lloyd | Compositions of clindamycin and benzoyl peroxide for acne treatment |
JP3265680B2 (en) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | Oral pharmaceutical composition |
US5230703A (en) | 1992-04-09 | 1993-07-27 | Staodyn, Inc. | Wound infection resolution utilizing antibiotic agents and electrical stimulation |
US5599557A (en) | 1992-04-30 | 1997-02-04 | Schering Corporation | Stable hydrated cephalosporin dry powder for oral suspension formulation |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
TW271400B (en) | 1992-07-30 | 1996-03-01 | Pfizer | |
MX9304638A (en) | 1992-07-31 | 1994-05-31 | Neose Pharm Inc | COMPOSITION TO TREAT AND INHIBIT GASTRIC AND DUODENAL ULCERS. |
US5817321A (en) | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
US5688516A (en) | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5422343A (en) | 1992-12-21 | 1995-06-06 | Otsuka Pharmaceutical Factory, Inc. | Prophylactic and therapeutic composition for MRSA infection |
JP3319800B2 (en) | 1993-02-01 | 2002-09-03 | 辻本化学工業株式会社 | Anti-resistant Staphylococcus aureus compounds |
US5414014A (en) | 1993-04-08 | 1995-05-09 | Innova Biomed, Inc. | Methods for efficacious removal of attached, sucking antropods from human dermis |
AU7966694A (en) | 1993-07-21 | 1996-05-02 | University Of Kentucky Research Foundation, The | A multicompartment hard capsule with control release properties |
JPH09500645A (en) | 1993-07-22 | 1997-01-21 | ワーナー−ランバート・コンパニー | Controlled release tacrine drug delivery system and method of making same |
CA2101241C (en) | 1993-07-23 | 1998-12-22 | Jonathan P. Wong | Liposome-encapsulated ciprofloxacin |
US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
US6183778B1 (en) | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
US5490962A (en) | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5518680A (en) | 1993-10-18 | 1996-05-21 | Massachusetts Institute Of Technology | Tissue regeneration matrices by solid free form fabrication techniques |
US6280771B1 (en) | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
US6251647B1 (en) | 1993-12-06 | 2001-06-26 | The Rockefeller University | Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof |
AU1398295A (en) | 1993-12-06 | 1995-06-27 | Rockefeller University, The | Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5393765A (en) | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
GB9402203D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
DE4404018A1 (en) | 1994-02-09 | 1995-08-10 | Merck Patent Gmbh | Protected release dosage forms containing clindamycin palmitate |
US5466446A (en) | 1994-02-16 | 1995-11-14 | Stiefel Laboratories, Inc. | Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof |
US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
CN1149874A (en) | 1994-04-01 | 1997-05-14 | 迈克罗赛药品公司 | Cephalosporin antibiotics |
GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
GB9408117D0 (en) | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
US5856474A (en) | 1994-04-25 | 1999-01-05 | Biochemie Gesellschaft, M.B.H. | Cephalosporin synthesis |
MX9605419A (en) | 1994-05-06 | 1997-12-31 | Pfizer | Liquid detergent containing polyhydroxy fatty acid amide and toluene sulfonate salt. |
FR2722098B1 (en) | 1994-07-06 | 1996-08-23 | Cird Galderma | NEW MEDICINES BASED ON METRO-NIDAZOLE OR A SYNERGETIC MIXTURE OF METRONIDAZOLE AND CLINDAMYCIN |
GB9416600D0 (en) | 1994-08-17 | 1994-10-12 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5543417A (en) | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
US5827531A (en) | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5872104A (en) | 1994-12-27 | 1999-02-16 | Oridigm Corporation | Combinations and methods for reducing antimicrobial resistance |
US5702895A (en) | 1995-01-19 | 1997-12-30 | Wakunaga Seiyaku Kabushiki Kaisha | Method and kit for detecting methicillin-resistant Staphylococcus aureus |
US20030083733A1 (en) | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
CN1170596C (en) | 1995-05-02 | 2004-10-13 | 大正制药株式会社 | Composition for oral administration |
US5755753A (en) | 1995-05-05 | 1998-05-26 | Thermage, Inc. | Method for controlled contraction of collagen tissue |
US6057291A (en) | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US6132768A (en) | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
US6013507A (en) | 1995-07-10 | 2000-01-11 | The Rockefeller University | Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof |
US6136587A (en) | 1995-07-10 | 2000-10-24 | The Rockefeller University | Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof |
US5985643A (en) | 1996-07-10 | 1999-11-16 | The Rockefeller University | Auxiliary gene and protein of methicillin resistant bacteria and antagonists thereof |
US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
US5780058A (en) | 1995-07-21 | 1998-07-14 | Alza Corporation | Oral delivery of discrete units |
US5919489A (en) | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5756473A (en) | 1995-11-21 | 1998-05-26 | Abbott Laboratories | 6-O-methyl erythromycin D and process for making |
US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5998194A (en) | 1995-12-21 | 1999-12-07 | Abbott Laboratories | Polyketide-associated sugar biosynthesis genes |
SE9600072D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
JP2000513209A (en) | 1996-02-16 | 2000-10-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antimicrobial peptides and methods of use |
JP3957338B2 (en) | 1996-02-23 | 2007-08-15 | 株式会社カイノス | Diagnostics |
US5951588A (en) | 1996-02-29 | 1999-09-14 | Moenning; Stephen P. | Apparatus and method for protecting a port site opening in the wall of a body cavity |
US5766220A (en) | 1996-02-29 | 1998-06-16 | Moenning; Stephen P. | Apparatus and method for protecting a port site opening in the wall of a body cavity |
TWI225402B (en) | 1996-03-13 | 2004-12-21 | Biochemie Gmbh | Auxiliary-free agglomerates |
US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
US5837829A (en) | 1996-04-02 | 1998-11-17 | Abbott Laboratories | 9-oximesilyl erythromycin a derivatives |
US5808017A (en) | 1996-04-10 | 1998-09-15 | Abbott Laboratories | Process for preparing erythromycin A oxime |
US5719132A (en) | 1996-06-27 | 1998-02-17 | Bristol-Myers Squibb Company | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil |
US5780446A (en) | 1996-07-09 | 1998-07-14 | Baylor College Of Medicine | Formulations of vesicant drugs and methods of use thereof |
US5858986A (en) | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
US5844105A (en) | 1996-07-29 | 1998-12-01 | Abbott Laboratories | Preparation of crystal form II of clarithromycin |
GB9617780D0 (en) | 1996-08-24 | 1996-10-02 | Smithkline Beecham Plc | Method of treatment |
JP2002514183A (en) | 1996-09-17 | 2002-05-14 | スーパージェン・インコーポレーテッド | Phospholipid drug derivatives |
IL119627A (en) | 1996-11-17 | 2002-03-10 | Yissum Res Dev Co | PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT |
US5840760A (en) | 1996-11-19 | 1998-11-24 | Florida Atlantic University | materials and methods for controlling methicillin-resistant Staphylococcus aureus microbes |
IT1289160B1 (en) | 1997-01-08 | 1998-09-29 | Jagotec Ag | FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF |
US5945405A (en) | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
US6296873B1 (en) | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
US5980942A (en) | 1997-01-23 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release matrix tablet formulations of carbamazepine |
US5864023A (en) | 1997-02-13 | 1999-01-26 | Abbott Laboratories | 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives |
US20020106412A1 (en) | 2000-07-10 | 2002-08-08 | Therics, Inc | Method and materials for controlling migration of binder liquid in a powder |
US20050064033A1 (en) | 1997-04-11 | 2005-03-24 | Notario Gerard F. | Extended release formulations of erythromycin derivatives |
US6010718A (en) | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6551616B1 (en) | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US6162463A (en) * | 1997-05-01 | 2000-12-19 | Dov Pharmaceutical Inc | Extended release formulation of diltiazem hydrochloride |
US6406880B1 (en) | 1997-05-02 | 2002-06-18 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
US5877243A (en) | 1997-05-05 | 1999-03-02 | Icet, Inc. | Encrustation and bacterial resistant coatings for medical applications |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
ATE302597T1 (en) | 1997-06-06 | 2005-09-15 | Depomed Inc | STOMACH-RESIDENT ORAL DOSAGE FORMS OF WATER-SOLUBLE DRUGS WITH CONTROLLED RELEASE |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
US6503709B1 (en) | 1997-07-03 | 2003-01-07 | Id Biomedical Corporation | Methods for rapidly detecting methicillin resistant staphylococci |
US6265394B1 (en) | 1997-07-31 | 2001-07-24 | Bristol-Myers Squibb Company | Bis quaternary MRSA cephem derivatives |
US6630498B2 (en) | 1997-08-06 | 2003-10-07 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation |
US6110925A (en) | 1997-08-07 | 2000-08-29 | Research Corporation Technologies, Inc. | Antibiotic for methicillin resistant bacteria |
EP1003476B1 (en) | 1997-08-11 | 2004-12-22 | ALZA Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US5929219A (en) | 1997-09-10 | 1999-07-27 | Abbott Laboratories | 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same |
US6605751B1 (en) | 1997-11-14 | 2003-08-12 | Acrymed | Silver-containing compositions, devices and methods for making |
US5852180A (en) | 1997-11-17 | 1998-12-22 | Abbott Laboratories | Chemical synthesis of 6-O-alkyl erythromycin A |
US6558699B2 (en) | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
IL135792A0 (en) | 1997-12-01 | 2001-05-20 | Abbott Lab | 6-o-alkyl derivatives of erythronolide b |
US5932710A (en) | 1997-12-01 | 1999-08-03 | Abbott Laboratories | Process for preparing 6-O-alkyl-9-oxime erythromycin B |
US5892008A (en) | 1997-12-16 | 1999-04-06 | Abbott Laboratories | Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives |
SE9704870D0 (en) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
US6294526B1 (en) | 1998-02-06 | 2001-09-25 | Alps Pharmaceutical Ind. Co., Ltd. | Use of flavone derivatives for induction of β-lactam-sensitivity of MRSA |
US6231875B1 (en) | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
US6288212B1 (en) | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
KR100377159B1 (en) | 1998-09-09 | 2003-08-19 | 한미약품공업 주식회사 | Method for preparing Form 2 of clarithromycin without residual solvent |
US6479496B1 (en) | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6740664B2 (en) | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
DE19845358A1 (en) | 1998-10-02 | 2000-04-06 | Roehm Gmbh | Coated drug forms with controlled drug delivery |
US6384081B2 (en) | 1998-10-09 | 2002-05-07 | Charles L. Berman | Treatment of diseases of the eye characterized by the formation of metalloproteinase |
US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
CA2348871C (en) | 1998-11-02 | 2009-04-14 | John G. Devane | Multiparticulate modified release composition |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
DE19852192C2 (en) | 1998-11-12 | 2003-04-24 | Bayer Ag | Aromatic copolyesters containing active ingredient |
US6159491A (en) | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6477410B1 (en) | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
US7127285B2 (en) | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6187768B1 (en) | 1999-06-01 | 2001-02-13 | Becton, Dickinson And Company | Kit for flushing medical devices and method of preparation |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US6946458B2 (en) | 1999-07-22 | 2005-09-20 | University Of South Florida | N-thiolated beta-lactams: novel antibacterial agents for methicillin-resistant Staphylococcus aureus |
TWI232111B (en) | 1999-08-06 | 2005-05-11 | Upjohn Co | Intravaginal clindamycin ovule composition |
DE19938704C1 (en) | 1999-08-14 | 2001-10-31 | Ivoclar Vivadent Ag | Process for the production of reaction systems for implantation in the human and animal body as a bone substitute, which i.a. Contain calcium and phosphorus |
KR100322313B1 (en) | 1999-10-21 | 2002-02-06 | 민경윤 | Method of preparing form ii crystals of clarithromycin and clarithromycin formate used therein |
JP2003514019A (en) | 1999-11-15 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Carvedilol methanesulfonate |
US6627743B1 (en) | 1999-12-03 | 2003-09-30 | Abbott Laboratories | 6-O-methylerythromycin A crystal form III |
KR20020070991A (en) | 1999-12-16 | 2002-09-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | Process for preparing clarithromycin polymorph and novel polymorph ⅳ |
KR20020071012A (en) | 2000-01-11 | 2002-09-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | Processes for preparing clarithromycin polymorphs |
CN1404388A (en) | 2000-01-20 | 2003-03-19 | 德尔西斯药品公司 | Multi-step drug dosage forms |
US6284235B1 (en) | 2000-02-11 | 2001-09-04 | National Starch And Chemical Company Investment Holding Corporation | Bioadhesive composition |
US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6623758B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
US7025989B2 (en) | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
JP2003523372A (en) * | 2000-02-24 | 2003-08-05 | アドバンシス ファーマシューティカル コーポレイション | Antibiotics and antifungal compositions |
US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
US6991807B2 (en) | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
US20020004070A1 (en) | 2000-02-24 | 2002-01-10 | Rudnic Edward M. | Antineoplastic product, use and formulation thereof |
US6610328B2 (en) * | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
YU64202A (en) | 2000-02-29 | 2005-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
DE60122791T2 (en) | 2000-03-15 | 2007-10-04 | Hanmi Pharm. Co., Ltd. | Process for the preparation of non-pharmaceutical grade clarythromycin |
US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
DE60139256D1 (en) | 2000-05-03 | 2009-08-27 | Silva Joe D | Method and device for producing liquid administration forms |
WO2001087272A2 (en) | 2000-05-18 | 2001-11-22 | Therics, Inc. | Encapsulating a toxic core within a non-toxic region in an oral dosage form |
AU2001272935A1 (en) | 2000-05-31 | 2001-12-11 | Mayo Foundation For Medical Education And Research | Cobalamin compounds useful as antibiotic agents and as imaging agents |
PE20020044A1 (en) | 2000-06-16 | 2002-01-30 | Upjohn Co | THIAZINE OXAZOLIDINONE |
WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
US6375982B1 (en) | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
US6696426B2 (en) | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
IN192748B (en) | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
US6767899B1 (en) | 2000-08-29 | 2004-07-27 | Leiner Health Services Corp. | Composition and method for treatment of conditions having an inflammatory component |
AU2001291526A1 (en) | 2000-09-22 | 2002-04-02 | Galephar M/F | Sustained release composition containing clarithromycin |
AU2002211536A1 (en) | 2000-10-06 | 2002-04-15 | Dusan Ninkov | Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
AR031135A1 (en) | 2000-10-10 | 2003-09-10 | Upjohn Co | TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
US7105174B2 (en) | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7108859B2 (en) | 2000-10-13 | 2006-09-19 | Advancis Pharmaceutical Corporation | Antineoplastic product, use and formulation thereof |
US7074417B2 (en) | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US7157095B2 (en) | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
US6565873B1 (en) | 2000-10-25 | 2003-05-20 | Salvona Llc | Biodegradable bioadhesive controlled release system of nano-particles for oral care products |
US6497901B1 (en) | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
CA2432797C (en) | 2000-12-18 | 2014-02-04 | David J. Yang | Local regional chemotherapy and radiotherapy using in situ hydrogel |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
US20020119168A1 (en) | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
US20020197314A1 (en) | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
IL157634A0 (en) | 2001-03-13 | 2004-03-28 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms containing glucocorticosteroid |
US6777420B2 (en) | 2001-06-15 | 2004-08-17 | Microbiotix, Inc. | Heterocyclic antibacterial compounds |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US20030124196A1 (en) | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030073826A1 (en) | 2001-08-28 | 2003-04-17 | Chao Robert S. | Crystaline clindamycin free base |
WO2003017981A1 (en) | 2001-08-29 | 2003-03-06 | Ranbaxy Laboratories Limited | Controlled release formulation of clarithromycin or tinidazol |
CA2405918A1 (en) | 2001-10-01 | 2003-04-01 | Ind-Swift Limited | Controlled release macrolide pharmaceutical formulations |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
JP4845340B2 (en) | 2001-10-29 | 2011-12-28 | マサチューセッツ インスティテュート オブ テクノロジー | System and method for uniaxial compression of articles such as three-dimensional printed dosage forms |
EP1441703B1 (en) | 2001-10-29 | 2018-01-03 | Massachusetts Institute of Technology | Zero-order release profile dosage form manufactured by three-dimensional printing |
US20030091627A1 (en) | 2001-10-31 | 2003-05-15 | Vinay Sharma | Rate-controlled delivery of macrolides |
AU2002357366A1 (en) | 2001-12-20 | 2003-07-09 | Pharmacia Corporation | Multiple-pulse extended release formulations of clindamycin |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
AR038575A1 (en) | 2002-02-22 | 2005-01-19 | Pharmacia Corp | OPHTHALM FORMULATION WITH NEW RUBBER COMPOSITION |
WO2003075852A2 (en) * | 2002-03-07 | 2003-09-18 | Advancis Pharmaceuticals Corporation | Antibiotic composition |
AU2003214506A1 (en) | 2002-04-03 | 2003-10-13 | Ranbaxy Laboratories Limited | Clarithromycin formulations having improved bioavailability |
WO2003105810A1 (en) | 2002-06-14 | 2003-12-24 | Andrx Corporation | Pharmaceutical compositions for drugs having ph-dependentsolubility |
US20040033262A1 (en) | 2002-08-19 | 2004-02-19 | Orchid Health Care | Sustained release pharmaceutical composition of a cephalosporin antibiotic |
US20040091528A1 (en) | 2002-11-12 | 2004-05-13 | Yamanouchi Pharma Technologies, Inc. | Soluble drug extended release system |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
US20040253249A1 (en) | 2003-04-02 | 2004-12-16 | Rudnic Edward M. | Pulsatile transdermally administered antigens and adjuvants |
US7476403B2 (en) | 2003-06-16 | 2009-01-13 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US20050053658A1 (en) | 2003-09-09 | 2005-03-10 | Venkatesh Gopi M. | Extended release systems for macrolide antibiotics |
US7455840B2 (en) | 2003-11-19 | 2008-11-25 | The Scripps Research Institute | Compositions and methods to reduce mutagenesis |
WO2005070940A2 (en) | 2004-01-13 | 2005-08-04 | Cumbre Pharmaceuticals Inc. | Rifamycin derivatives effective against drug-resistant microbes |
EP1723150A1 (en) | 2004-01-13 | 2006-11-22 | Cumbre Pharmaceuticals Inc. | Rifamycin imino derivatives effective against drug-resistant microbes |
US7256187B2 (en) | 2004-03-10 | 2007-08-14 | Cumbre Pharmaceuticals Inc. | Rifamycin C-11 oxime derivatives effective against drug-resistant microbes |
US7265107B2 (en) | 2004-03-10 | 2007-09-04 | Cumbre Pharmaceuticals Inc. | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes |
US7250413B2 (en) | 2004-04-26 | 2007-07-31 | Cumbre Pharmaceuticals Inc. | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes |
US7202246B2 (en) | 2004-06-09 | 2007-04-10 | Cumbre Pharmaceuticals Inc. | Spiro-rifamycin derivatives targeting RNA polymerase |
CN101031572B (en) | 2004-07-22 | 2010-12-08 | 坎布里Ip风险投资有限合伙公司 | (R/S) rifamycin derivatives, their preparation and pharmaceutical compositions |
-
2005
- 2005-07-01 AU AU2005269981A patent/AU2005269981A1/en not_active Abandoned
- 2005-07-01 CA CA002572292A patent/CA2572292A1/en not_active Abandoned
- 2005-07-01 WO PCT/US2005/023831 patent/WO2006014427A1/en active Search and Examination
- 2005-07-01 EP EP05769422A patent/EP1771158A4/en not_active Withdrawn
- 2005-07-01 JP JP2007519542A patent/JP2008505124A/en active Pending
- 2005-07-01 US US11/173,929 patent/US8715727B2/en active Active
-
2014
- 2014-03-28 US US14/228,817 patent/US20140212490A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8715727B2 (en) | 2014-05-06 |
EP1771158A4 (en) | 2008-03-12 |
CA2572292A1 (en) | 2006-02-09 |
EP1771158A1 (en) | 2007-04-11 |
AU2005269981A1 (en) | 2006-02-09 |
WO2006014427A1 (en) | 2006-02-09 |
US20060003005A1 (en) | 2006-01-05 |
JP2008505124A (en) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8715727B2 (en) | Tablet for pulsed delivery | |
US6544555B2 (en) | Antibiotic product, use and formulation thereof | |
US6730320B2 (en) | Tetracycline antibiotic product, use and formulation thereof | |
US6667057B2 (en) | Levofloxacin antibiotic product, use and formulation thereof | |
US6984401B2 (en) | Antiviral product, use and formulation thereof | |
US6669948B2 (en) | Antibiotic product, use and formulation thereof | |
US8303988B2 (en) | Antifungal once-a-day product, use and formulation thereof | |
US6663891B2 (en) | Erythromyacin antibiotic product, use and formulation thereof | |
US6667042B2 (en) | Fluroquinilone antibiotic product, use and formulation thereof | |
US6663890B2 (en) | Metronidazole antibiotic product, use and formulation thereof | |
US6991807B2 (en) | Antibiotic composition | |
US7025989B2 (en) | Multiple-delayed released antibiotic product, use and formulation thereof | |
US6623758B2 (en) | Cephalosporin-metronidazole antibiotic composition | |
AU2002359768A1 (en) | Antibiotic product, use and formulation thereof | |
AU2006201923C1 (en) | Therapeutic product, use and formulation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |